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Carbohydrate binding agents that target viral envelope glycans are being 
studied for their potential use as microbicides and antiviral therapeutics.  
Griffithsin is a lectin originally identified in a red alga Griffithisia sp. Multiple 
studies have shown that GRFT inhibits HIV-1, Coronaviruses, Hepatitis C, 
influenza and Ebola virus replication in vitro. This antiviral activity suggests 
potential uses in chemoprophylaxis and disease treatment.  However, safety of 
GRFT administration has not been extensively studied.   In vivo testing--chronic 
subcutaneous treatment as well as single dose subcutaneous, oral, and 
intravenous administrations of Griffithsin in Sprague Dawley Rats (Rattus 
Norvegicus)--was used to assess Griffithsin’s pharmacokinetic properties and to 
predict whether use of Griffithsin for antiviral treatment might be safe and 
effective. Based on histological, serological, and biochemical data derived from 
these experiments, Griffithsin is generally well tolerated.  However, protein 
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binding assays revealed interactions with complement and apolipoproteins and 
calorimetric assays revealed changes in serum thermograms that may require 
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INTRODUCTION AND BACKGROUND 
 
A number of enveloped viruses continue present significant threats to 
public health in the United States and the developing world.  Discovery and 
development of antivirals with broad spectrum activity is important for both 
antiviral prophylaxis as well as for therapy.  
Perhaps the most significant viral epidemic in the recent past is Human 
Immunodeficiency Virus (HIV).  With no effective vaccine, HIV-1, affects over 35 
million people worldwide, and still claims the lives of millions of people per year 
despite effective treatment options [1]. In the United States alone, approximately 
50,000 new infections still occur yearly, with over 50% of those infections being 
among men who have sex with men (MSM).  Other enveloped viruses also cause 
persistent viral infections and present serious threats to public health.  Aside from 
HIV-1, the most clinically significant persistent viral infections are caused by 
Hepatitis C Virus (HCV), and human herpesviruses such as cytomegalovirus 
(CMV), Karposi’s sarcoma-associated herpesvirus (KSHV), and type 2 herpes 
simplex virus (HSV-2).  Viruses that cause chronic, often life-long infections have 
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all needed to evolve strategies to evade the host immune response.  Viruses use 
a diverse range of immune evasion strategies, from blocking the interferon 
response through induction of interfering ribonucleic acids (RNAs) [2-7]. For 
example, HIV-1 employs many of these strategies ranging from inhibition of 
humoral immune responses by complement to antigenic variation attributable to 
low fidelity reverse transcriptase [8, 9]. Further, HIV-1 downregulates interferon 
(IFN) production to prevent an immune response [10], as well as possibly 
encodes silencing RNAs [11, 12].  Many of the viruses that persist for long 
periods of time display dense glycan shields on their envelopes to evade humoral 
immune responses by display of “self” epitopes that occlude functionally 
important domains of the envelope proteins, and in some cases to suppress 
induction of an immune response.  
Enveloped viruses from taxonomic families not necessarily linked by a 
common evolutionary history often display heavily glycosylated envelope 
glycoproteins. Dense, asparagine-linked (N-linked) glycans attached to viral 
surface proteins are a common structure amongst these viruses [13, 14].  These 
glycans present on viral envelope proteins have roles in host immune evasion 
and modulation, as well as stabilization of viral envelope structures [15-17].  In 
the case of HIV, oligomannose glycans have been theorized to assist in immune 
evasion through presentation “self” epitopes [18], as well as down-regulation of 
INF production and immunosuppressive cytokine induction under some 
circumstances [2, 10, 19, 20].     
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While glycans are structurally important for these viruses, they also 
present new targets for antiviral agents.  Agents which could selectively bind 
these glycans could thus be attractive targets for ongoing antiviral research – 
both as a preventative as well as a treatment [21]. In recent years, natural 
product derived lectins have been recognized for this very purpose [14, 22-24]. 
These lectins have been observed to inhibit viral transmission by binding to the 
specific N-linked glycans present on the surface of the viral envelopes [14].  In so 
doing they have the effect of preventing viral fusion and entry [22, 25-27].  
Outcomes of lectin therapy have also generally been positive. Animal 
survival and amelioration of viral infection has been observed in a number of viral 
challenges.  Treatment with cyanovirin (CV-N) conveyed marked survival 
benefits in a murine influenza challenge [28].  Treatment with large 
concentrations of human mannose binding lectin (MBL) conveyed a survival 
benefit versus Ebola virus challenge in mice [29].  Additionally, HCV infection has 
been modestly inhibited through lectin therapy [30, 31].   
Griffithsin (GRFT) is a lectin originally identified from the red algae 
Griffithisae sp [32].  Now recombinantly produced in tobacco plants, GRFT is a 
candidate topical microbicide and systemic therapeutic [33, 34].  In vitro studies 
into GRFT’s anti-HIV-1 activity have demonstrated an average inhibitory EC50 of 
40 pM [32].  While initially investigated as a microbicide, systemic administration 
studies are currently underway to evaluate potential uses of GRFT in antiviral 
therapy [34].  
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Given GRFT’s potent antiviral activity and low immunogenicity, GRFT has 
the diverse potential applications, including use as a systemic anti-viral therapy, 
chemoprophylaxis, or microbicidal agent [35-37].  The purpose of this 
dissertation is to explore GRFT’s potential usage as a pre-exposure prophylaxis 
and systemic therapeutic for enveloped viruses possessing high-mannose N-
linked glycans.  While GRFT has activity against multiple viruses, this 
dissertation focuses on GRFT in the context of HIV-1 infection given robust in 
vitro assays to measure and analyze GRFT’s anti-HIV activity in serum and other 
biological products.  The specific aims of these studies included:  evaluation of 
GRFT’s practical pharmacokinetic parameters to elucidate how method of 
administration may impact GRFT’s utility; evaluation of GRFT’s potential as an 
orally dosed rectal microbicide through gastric lavage of different concentrations 
of GRFT in rats; evaluation of GRFT’s systemic impacts both in the presence and 
absence of an antibody response with accompanying intermediate-term dosing; 
and identification of GRFT’s potential endogenous serum protein binding 
partners through affinity purification; as well as evaluation as to whether 
Differential Scanning Calorimetry is capable of revealing alterations in serum 
protein interactions following both chronic systemic administration and serum 
spiking of GRFT.  
Glycosylation States 
Glycosylation is enzymatic addition of complex carbohydrate chains to 
organic molecules, such as proteins [38].  These additions assist in maintaining 
proper protein folding, increase protein stability, and contribute to protein 
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functionality [39]. Furthermore, glycosylation can result in greater hydrophilicity.  
Viral glycosylation can also alter infectivity and viral fitness [40]. 
Glycosylation is a covalent post-translational modification that can occur in 
either the Golgi apparatus or the endoplasmic reticulum and is fundamental to 
many biological processes [29]. This modification process can result in five 
different types of glycans (glycoforms) can result: N-linked, O-linked, C-linked, 
glipiated, or phospho-glycans [29].  The glycoform relevant to the studies at hand 
are of the N-linked variety, given GRFT’s high affinity for oligomannose N-linked 
glycans. 
N-linked glycosylation begins with the addition of a 14 unit oligosaccharide 
precursor to an asparagine in a polypeptide chain.  The signal for N-linked 
glycosylation occurs through one of two sequences: Asn-X-Ser or Asn-X-Thr, 
where X can be any amino acid except proline [41].  The general branched 
carbohydrate chain contains 3 glucose, 9 mannose, and 2 N-acetylglucosamine 
molecules attached to a carrier molecule (a dolichol), and transferred to the 
appropriate signal sequence on the protein as it is translocated into the ER 
lumen [42]. 
Saccharide compositions between glycans of the same linkage type may 
also vary, leading to High-mannose, Hybrid, or Complex glycans (with the 
terminal structure presented after editing determining the glycan subtype) (Figure 
1.1) [29]. High-mannose glycans exclusively present mannose on the terminal 
portions of the sugar, and contain 5-9 mannose residues [29] (Figure 1.1 A &B).  
No N-acetyl glucosamine residues are presented. As the initial state for many 
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glycans, further editing occurs which result in either Complex (Figure 1.1 D) or 
Hybrid glycans (Figure 1.1C) [29].  This editing is thought to depend on 
accessibility to multiple saccharide-modifying proteins present in the Golgi [29].   
Further editing results in either Hybrid glycans – where at least one mannose 
residue and one N-acetylglucosamine are presented, or Complex glycans [29]. 
Complex glycans, which do not have mannose terminal residues, can have 
multiple N-acetyl glucosamines or other terminal sugar structures presented [29]. 
Endogenous glycans have many vital physiological roles.  Glycans can 
prevent self-recognition and autoimmunity[43].  Functionally, glycans can 
stabilize protein folds as well as become vital parts of extracellular matrix [44].  
Further, glycans can function in cell trafficking and communication through 
recognition of glycan binding proteins[45].  In the case of antibodies and other 
circulating proteins, serum half-life and cell receptor interaction may be 
influenced by glycosylation [46-49]. 
 
Viral Glycosylation 
Upon taking over the cellular machinery upon infection, virally produced proteins 
are also known to be glycosylated.  In the case of HCV, a number of envelope 
proteins are glycosylated [17, 50].  Further, as mentioned previously, these viral 
glycans assist in immune evasion, with the loss of the glycans related with 
increased susceptibility to antibody neutralization [17, 51, 52].  Influenza virus 
also present glycosylated glycans [40].  Influenza hemagglutinin (HA) initiates the 
infection process by binding to cellular receptors and is known to possess 
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multiple glycosylation sites which has been linked to virulence in mice[53].  The 
Severe Acute Respiratory System Coronavirus(SARS-CoV) possesses a number 
of glycosylation sites, particularly in the S glycoprotein necessary for cellular 
binding[54, 55].  Ebola virus possesses both N- and O-linked glycans[56, 57].   
 
HIV-1 – A virus possessing Oligomannose N-linked glycans 
HIV-1, a lentivirus of the retrovirus family, continues to spread worldwide [58].  
HIV’s genome consists of nine genes[59].  Six genes in the HIV genome:  tat, 
rev, nef, vif, vpr and vpu code for viron processing [59]  Whereas, Gag, Pol, and 
Env encode structural and functional proteins [59].  Many of the proteins 
produced are precursors that require additional modification.  Gag encodes 
protein which is cleaved into matrix (p17), capsid (p24), nucleocapsid (p7), and 
p6 [59].  Similarly replication proteins associated with cDNA synthesis and cDNA 
integration are generated as precursors cleaved to produce viral protease, 
reverse transcriptase and integrase [59].   
 Virion surface glycoproteins gp120 and gp41 are encoded on the Env 
gene. These glycoproteins are initially synthesized as a 160kDa glycoprotein 
precursor protein, requiring cleavage before assembly into a spike [59].  
Following glycosylation in the endomembrane system, gp160 is enzymatically 
cleaved into gp120 and gp41 [43]. Trimerization of three molecules of gp41 with 
gp120 molecules spikes on the viral envelope for interacting with CD4 receptor 
molecules [59]. 
GP120 structure and glycosylation 
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Gp120 protein of HIV is highly glycosylated, with an average of 24 
glycosylation sites occupied [55].  Further, those glycans are almost entirely of 
the high-mannose variety [13, 60].  These glycans can greatly impact viral 
infectivity and fitness.  For example, an increase in potential N-linked 
glycosylation sites can result in increased viral fitness by obscuring binding sites 
recognized by antibodies [56]. Additionally, viruses isolated from early time points 
in infection tend to be less heavily glycosylated than viruses isolated from later 
time points [57, 58].   
 
HIV Infection  
Cellular binding is the first step in the process of HIV infection.   Viral 
particles with reduced numbers of N-linked glycans infect activated T-cells and 
dendritic cells in the genital mucosa [61-64]. CD4+ T cell infection results in 
migration of the virus to gut-associate lymphoid tissues [65, 66].  There acute 
infection takes hold as gut-associated T-cells possessing the α4β7 gut homing 
integrin are infected and depleted [64]. 
The routes of sexual exposure and transmission may vary.  Vaginal 
transmission is the most common route of transmission worldwide, though in the 
United States the majority of new infections occur via rectal exposure[67]. In 
vaginal transmission, the cervix is a major site for HIV-1 transmission as rich in 
HIV-1 target cells [68-70].  However, receptive anal intercourse provides the 
greatest probability of transmission [71, 72].   Fragile rectal tissue which can be 
damaged by intercourse, and a large population of T cells and dendritic cells 
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resident in the rectal mucosa contribute to high probability of productive infection 
[71, 73-77]. 
 The biochemical steps of cellular infection begin with gp120 present on 
the envelope of HIV binding with the CD4 receptor molecule expressed on the 
surface of mature CD4+ T cells, macrophages and dendritic cells [78-80].  Upon 
binding, the CD4 receptor molecule undergoes conformational changes with 
allow for interaction with either of two 7-transmembrane spanning chemokine 
receptors, CCR5 or CXCR4 [81-83].  Co-receptor engagement and binding leads 
to a second conformational change in the viral envelope spike, altering the state 
of gp41 [84, 85].  This alteration of gp41 leads to insertion of the N-terminal 
domain of gp41 into the cellular membrane.  This insertion triggers formation of a 
six-helix bundle that provides the energy for cellular fusion. [84-86].  Upon fusion, 
the viral capsid releases two copies of RNA, reverse transcriptase, integrase, 
and viral protease.  Reverse transcriptase acts to convert the RNA into DNA 
while Integrase cleaves host DNA and integrates the new viral DNA into the host 
cell genome.  Later, viral protease acts to cleave precursor polyproteins into 
functional proteins for new virion packing and assembly. 
 Within weeks of infection, some persons display Acute Retroviral 
Syndrome associated with primary HIV infection.  During that period, a large 
burst of viral replication occurs as the immune system reacts to the infection, 
attempting to eliminate the virus and infected cells.  During this period, 
nonspecific symptoms such as fever, rash, body aches occur as a consequence 
of immune system activation.  After a number of days to weeks, symptoms 
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resolve, however the immune system is remains in a persistent inflammatory 
state.  Despite a lack of outward symptoms, a slow but steady decrease in CD4+ 
cells occurs over a number of years.  During this time, a gradual increase in viral 
load accompanies the decrease in CD4+ t cells.   
 
Prevention Methods and Antiviral treatments 
 Pharmacological strategies are currently in use for the treatment of many 
of enveloped viruses, with small molecule pharmaceuticals designed to block 
specific events in the viral life cycle.  These strategies include 
preventing/reducing viral replication, preventing virion processing and maturation, 
as well as preventing viral entry into cells.   
HIV-1 currently has many treatment options available for infected 
individuals with the goal of suppressing viral replication below the limits of 
detection. However, maintenance of an undetectable viral load may be difficult to 
maintain due to drug side effects, drug adherence, and emergence of drug 
resistant virions.  As such, a long acting adjuvant treatment acting upon a novel 
drug target may be useful for those with adherence issues, or those with few 
treatment options left.  As such, anti-viral lectins targeting N-linked oligomannose 
glycans present on HIV-1 gp120 spike proteins may be a new treatment option 
for maintaining an undetectable viral load, and thus maintaining the health 
benefits an undetectable viral load brings. 
Drugs to suppress HIV infection currently include non-nucleoside reverse 
transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, protease 
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inhibitors, integrase inhibitors, and fusion/entry inhibitors.  Collectively known as 
Highly Active Anti-Retroviral Therapy (HAART), these medications, when given in 
combination therapy, offer the potential for infected individuals to live a normal 
lifespan [87].  The goal of HAART is to as suppress viral load to undetectable 
levels.  In many cases, this leads to preservation of immune function [88]. 
Further, due to continued thymic output, durable viral suppression is often 
accompanied by a restoration of CD4+ cell populations [89, 90]. However, even 
in those who are virally suppressed, as significant subset, known as 
immunological non-responders, fail to see full immune system recovery [88, 91]. 
Prior to the initiation of HAART, genetic testing is conducted to determine 
HIV-1 drug resistances.  With this knowledge in hand, the typical regimen 
consisting of 3 or more drugs of at least two classes is chosen [92, 93].  After 
initiation of HAART, the majority of patients see a very rapid decline in viral load 
levels as well as an increase in CD4+ T cells [94, 95]. Many individuals can 
achieve undetectable viral loads with vigilant adherence to therapy [94].  Further, 
increases in CD4 cells counts can continue for years after durable viral 
suppression is achieved [88, 95-97].  Nonetheless, lifetime adherence to therapy 
is currently required. 
One complicating factor in disease management is that once HIV-1 is 
systemically established, viral reservoirs appear to make systemic eradication of 
the virus impossible [98-101]. Viral reservoirs are believed to be the latent 
infection of long lived memory cells.  However, it is also possible that a low level 
viremia intermittently continues or a combination of both of those factors [98-
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102].  The practical effect of this latent infection is seen through the fact that 
shortly after discontinuing HAART, viral load levels rebound in the majority of 
patients.   
In addition to viral rebound after discontinuation of therapy, intervening 
periods of low level viral replication can occur.  Despite durable suppression of 
viral replication, T-cell activation during times of illness or infection can cause 
bursts of HIV-1 replication activity in infected cells[94].  The clinical significance 
of these “blips” are currently not thought to be relevant[103].  However, it is 
possible that detectable viremia may be indicative of the acquisition of viral 
resistance[103].    
Nonetheless, many studies now support the notion that undetectable viral 
loads are the primary goal of treatment.  Studies have indicated that 
undetectable viral load levels could be even more important than CD4+ counts 
[104].  Thus a patient who is consistently undetectable in their viral load testing 
may need less periodic testing for CD4 counts [104]. As such, anti-viral agents, 
such as antiviral lectins, that could further prevent cell-to-cell transmission of HIV 
during periods intermittent or transient viremia may aid in maintaining 
undetectable viral loads.  
 
Pre-Exposure Prophylaxis (PrEP) 
 Recently, a new prevention method was approved for usage within the 
United States which validates the concept of patient pre-treatment with anti-viral 
agents to prevent HIV-1 infection.  Pre-exposure Prophylaxis (PrEP) is a 
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chemotherapeutic intervention that offers the promise of preventing HIV-1 
infection if used as directed [105, 106].  PrEP currently consists of administration 
of antiviral drugs to HIV negative persons at risk for infection [107].  Presently, 
Truvada (a combination of emtricitabine and tenofovir) is the only drug 
combination provided to high-risk, HIV-1 negative, individuals [96].  If taken daily 
as directed, PrEP has been observed to substantially reduce chances of HIV-1 
infection after exposure [105, 108].  Nonetheless, PrEP is not devoid of risks.  
Rarely, kidney damage and malfunction can occur which would necessitate 
cessation of PrEP [109-112].  As such, frequent kidney function testing is 
recommended [96].   As such, this emerging field prevention method is likely to 
increase as additional antiviral drug interventions are validated. 
 
Treatment as Prevention (TasP) 
A second concept which underscores the need to maintain undetectable 
viral loads is summarized as Treatment as Prevention (TasP) [113].  Preliminary 
results from the PARTNER study have shown no transmissions between 
individuals when the positive partner has an undetectable viral load [114].  While 
the final results of the study will not be available for a number of years, it appears 
that an undetectable viral load in a positive individual strongly correlates with 
infectiousness [115, 116].  As such, attaining and maintaining an undetectable 






Post Exposure Prophylaxis (PEP) 
Post Exposure Prophylaxis (PEP) has also been used successfully to 
prevent viral infection [117-120].  PEP consists of a month long course of anti-
retroviral medication after both occupational and nonoccupational exposures.  
With needlesticks being a common occupational exposure, PEP has been 
observed to be effective in preventing infection [120].  Further, in a non-
occupational exposure setting, such as condom breaks during intercourse, PEP 
has shown great efficacy [119].  However, it typically must be initiated within 48 
hours after exposure in order to reduce the odds of transmission. 
 
Entry Inhibitors 
Entry inhibitors that prevent viral fusion with its target cell at various 
phases of the viral entry process are currently being used in treatment and 
research.  These agents target proteins on either the HIV-1 virus or the cell.  
Targets include: gp120 of HIV-1, gp41 of HIV-1, and T-cell receptors and co-
receptors.  Entry inhibitors mechanistically present a barrier to infection through 
binding activity to viral or cellular receptors necessary for infection [33, 121]. 
Entry inhibitors that neutralize the virus, such as isolated broadly 
neutralizing monoclonal antibodies, are potential chemoprophylactic and 
therapeutics for HIV-1.  These broadly neutralizing antibodies recognize epitopes 
(such as gp41, V1V2-glycans, and the CD4 binding site) on the HIV-1 envelope 
and can neutralize multiple strains.  For instance, antibody b12 recognized the 
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CD4 binding site of HIV-1 [122], whereas 2G12 recognizes the outer domain 
glycan [123].  Other monoclonal antibodies, such as 3BNC117 and 10-1074, 
which target the CD4 binding site and V3 region respectively, have been 
examined both as monotherapy and together in a Macaque SHIV models [124]. 
When used individually, emergence of neutralization-resistant variants often 
limits their long term utility [124]. However, broadly neutralizing may hold promise 
when used in cocktails to treat chronic HIV infection [124, 125].  
While many entry inhibitors directly act on the virus, an alternative 
approach may include the competitive blockage of receptor or co-receptor 
molecules on HIV target cells. For example, Ibalizumab is a non-
immunosuppressive CD4-targeting IgG molecule [126-128]. Ibalizumab binds the 
CD4 molecule present on T-cells receptors in the D2 region [129, 130].  While 
blocking portions of the CD4 receptor, it does not interfere with binding of MHC II 
molecules or the gp120-- thus it does not interfere with normal immune function 
[129-131].   
Enfuvirtide, is a 36 amino acid peptide mimic of the HR2 fragment of gp41. 
Functionally it binds to the HR1 region of gp41 [132, 133].  Enfuvirtide  binding 
blocks formation of the six helix bundle required for the cellular fusion process 
[85].  While it is an injectible peptide fusion inhibitor [134],  it was approved for 
treatment of HIV infection in 2003 [135]. 
Maraviroc is CCR5 co-receptor antagonist [136-138].  Maraviroc binds to 
the transmembrane cavity of the CCR5 co-receptor, halting the co-receptor 
interactions necessary for viral fusion [139].  
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Entry Inhibitors – Antiviral Lectins  
Lectins are also being investigated as potential HIV-1 entry inhibitors [22].   
Lectins are highly specific carbohydrate binding proteins.  In animals, lectins can 
function in the immune system recognition of carbohydrates exclusively 
presented by pathogens.  For example, mannose binding lectin is protein of the 
innate system that activates complement or triggers pathogen opsonization [83].   
Antiviral lectins consist of a subset of lectins which bind to viral envelope 
glycans [22].  Among these are Griffithsin (GRFT), Scytovirin (SVN), Bananna 
lectin (BanLec), Concanavalin A (ConA), Cyanovirin-N (CVN), and Actinohivin  
[27, 140-142].  While different lectins have different carbohydrate targets, such 
as high-mannose glycans or complex glycans, lectins specific for HIV glycans are 
thought to bind high-mannose glycans of gp120, preventing cell fusion [21, 22, 
143].  
Despite their promise, lectin therapy may be challenging.  First, 
exogenous lectins, like Phytohemagluttinin (PHA), are well known to agglutinate 
red blood cells [144] and often induce mitogenic and cytotoxic effects [145].  
Second, lectins are often considered anti-nutrients given their sugar binding 
activities [146].  For example, large consumption of lectins can cause side effects 
such as diarrhea, nausea, and vomiting [147].  Finally, lectins may interact with 
leptin receptors, leading to leptin resistance [148]. 
In vitro studies with antiviral lectins have also identified a number of 
potential issues.  For instance, studies into CVN, which binds to alpha (1,2) 
mannose termini, have identified cell morphology changes in PBMC’s treated 
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with CVN as well as increased expression of cellular activation markers [149].  
These changes rendered the PBMCs more susceptible to HIV-1 infection by R5 
trophic variants.  Further, CVN was found to increase production in a number of 
cytokines.  BanLec, a potent anti-HIV-1 lectin with specificity for oligomannose 
glycans higher than (Man)6GlcNAc, has been found to be an agglutinating agent 
in rabbit erythrocytes as well as a powerful murine T-cell mitogen [150, 151]. 
In vivo studies with antiviral lectins has also identified challenges.  ConA, 
which has an anti-HIV-1 50% effective concentration (EC50) of approximately 
98nM has significant in vivo toxicity [25]. ConA binds high-mannose type, hybrid 
type and biantennary complex type N-glycans [152] and has been observed to 
strongly agglutinate many cell types, as well as has been identified as having 
fetal development toxicity in rats [153].  Further, investigation into ConA’s toxicity 
identified ConA as inducing focal hepatic necrosis, lymphoid atropy, and vascular 
endothelial damage at a 200-800 µg dosage in mice [154, 155]. 
In addition to potential toxicities associated with carbohydrate binding 
activity, lectins may induce allergic reactions and anaphylaxis.  Immune reaction 
to exogenous proteins are not uncommon [156].  The largest potential threat is 
anaphylaxis [82].  However, other, less life threatening immune reactions may 
also occur, such as the generation of neutralizing antibodies [82].     
Protein therapy-induced anaphylaxis has been observed with approved 
therapeutics Rituximab, Omalizumab, and alpha galactosidase A [157-160].      
These therapeutics are testament to the idea that despite the risks, the benefits 
of protein based therapy can weigh in favor of approval. Nonetheless, efforts to 
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reduce the chance of lethal reactions continue. For example, efforts into structure 
guided protein modifications to reduce immunogenicity have been theorized [161, 
162].  These modifications would lessen the potential for immune system 
recognition, thus reducing the possibility of an immune response [161, 162]. 
 
Griffithsin Structure and Mechanism of action 
GRFT is an antiviral lectin derived from the red algae Griffithsia sp, 
possessing a strong affinity for N-linked high mannose glycans [32, 33].  GRFT 
forms ~25kDa domain swapped homodimers in solution, with the first 16 amino 
acids of each monomer completing the B-prism fold of the other monomer [163]. 
These jacalin-like binding pockets are formed by 3, four stranded beta sheets, 
with an internal symmetry. A total of 6 mannose binding sites have been 
identified by X-ray crystallography of dimeric GRFT at 1.3A resolution [163, 164].  
The six carbohydrate binding pockets are equally split, with three carbohydrate 
binding pockets being located on opposite ends of the double-prism structure 
[163].  Atomic resolution crystal structures of an engineered monomeric GRFT 
have revealed that each monomer can bind to two different nonamannoside 
molecules through all three carbohydrate binding sites [163, 165].  Further, 
structural complexes of GRFT with saccharides have identified 3 virtually 
identical active sites on each monomer consisting of a GGSGG motif [166]. Upon 
dimeric folding, X-ray crystallography has also identified the geometries of the 
binding sites as being equilaterally triangular in shape [164].   
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In the case of HIV-1, GRFT’s inhibitory activity is associated to its binding 
of the almost exclusively high-mannose glycans present on gp120 protein [13, 
32].  Supporting this theory is the fact that lectin-resistant isolates of HIV have 
reduced numbers of glycosylation sites [16]. Additionally, a loss in antiviral 
activity was observed with monomerization of GRFT, suggesting that GRFT’s 
ability to cross link virions or gp120 proteins is key to its antiviral activity[167].  
This crosslinking of N-linked glycans present on the envelopes is thought to 
inhibit structural transitions required for viral entry.  GRFT has also been 
observed to inhibit HIV-1 transfer from dendritic cells (DC) receptor DC-SIGN to 
uninfected T-cells.  To date, GRFT is the most potent antiretroviral drug of any 
drug class for preventing transmission of cell-free and -associated HIV-1. 
  Prior work has suggested that GRFT can be cost effectively produced in 
tobacco plants [168, 169].  Additionally, prior studies have suggested GRFT’s 
weak immunogenicity and demonstrated low induction of inflammatory cytokines 
and chemokines in animal models [33, 169].  These studies have confirmed 
GRFT displays no human T-cell mitogenic activity, and unlike many other lectins 
does not induce production of pro-inflammatory cytokines in treated human 
peripheral blood mononuclear cells at >10,000 times antiviral concentrations [35, 
169].  
GRFT also has a notably broad spectrum of activity. Antiviral activity 
against HCV [30, 170], HIV-1 [32, 169, 171], HIV-2 [171],  and SARS-CoV [172] 
has been documented. Unpublished studies have also demonstrated activity 
versus influenza A virus, and several other enveloped viral pathogens (O’Keefe 
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BR, unpublished). For many of these diseases, GRFT has a markedly low in vitro 
inhibitory activity.  Against HCV, GRFT’s EC50 has been found to be 
approximately 13.9 nM [170].  Versus SARS-CoV, it has an EC50 of 48 nM. [163, 
172]. However, in the case of HIV-1, Griffithsin has an in vitro EC50 in the mid 
picomolar to low nanomolar range [16, 32, 169].   
General studies into GRFT’s systemic tolerance have also been 
encouraging.  We observed GRFT to be tolerable during a 10 day chronic dosing 
regimen [34].  This tolerability, seen in both mice and guinea pigs 
subcutaneously dosed with GRFT raises the potential for short term usage of 
GRFT as a prophylactic treatment.  Further, continued antiviral activity against 
HIV-env pseudoviruses and a long serum persistence of GRFT were observed 
[34].  These factors would support in vivo administration of GRFT in an exposure 
setting wherein amelioration or prevention of establishment of infection were the 
goal of therapy. 
GRFT’s antiviral activity has also been observed both ex vivo and in vivo.   
HIV-1 infection of human cervical explants has been prevented by topical 
application [169].  In vivo challenges in mice have also been positive, with activity 
versus: SARS-CoV (intranasal treatments) [172]; Japanese encephalitis virus 
(JEV) (intraperitoneal treatment) [173]; and HCV (subcutaneous treatment - 
mouse-human chimeric liver models) [30, 170]. 
With the short term tolerability of GRFT administration established, as well 
as the potential for viral inhibition in vivo, it is possible that GRFT may be useful 
in established infections.  Despite the advent of modern HAART, which can 
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suppress viral replication below currently detectible limits, new therapies are 
constantly  needed.  HIV’s propensity for mutation under drug pressure translates 
into an eventual viral breakthrough.  Further, as mentioned previously, during 
times of immune activation-such as a cold or infection, viral “blips” may occur in 
which a person with a previously undetectable viral load displays a detectable 
viremia[94, 103].   Accordingly, agents which could further reduce the chance of 
drug resistant isolate proliferating may assist in maintaining viral undetectable 
viral loads – a key factor in infectiousness. Further, given the current window of 
opportunity for preventing establishment of a productive infection, additional 
drugs that could be used for PrEP or PEP may have utility in both occupational 
and nonoccupational settings. However, for GRFT’s usage in established 
infections, long term systemic impacts, including potential immune activation 
which may trigger low level viremia, a neutralizing antibody response, or 













This work presents a compilation of work investigating the overarching 
hypothesis that GRFT is a candidate for systemic antiviral therapy.  However, a 
number of unknowns currently exist.  In Chapter 2, we review the animal studies 
which laid the foundation for the present evaluation of GRFT’s systemic 
tolerance. In Chapter 3, we examine the practical pharmacokinetics of GRFT in 
Sprague Dawley rats and its potential impact upon method of administration, 
timing of dosage, and method of excretion.  In Chapter 4, we examine the 
tolerability of sub-chronic dosing of GRFT in Sprague Dawley rats, with an 
immune response primed by pre-immunization with GRFT as well as passive 
immunization with anti-GRFT IgG.  Finally in Chapter 5, we examine GRFT’s 
biochemical interactions through Differential Scanning Fluorometry and Affinity 
Purification, as well as examination of the effects on endogenous proteome 
interactions through Differential Scanning Calorimetry.  The findings in this 
Dissertation lay a foundation for further study to validate GRFT’s usage as a 






Figure 1.1 N-linked Glycans – structural arrangement of subtypes.  Schematics 
illustrating examples of different N-linked glycans.  Oligommanose Glycans –
Man9 (A) and Man5 (B) present exclusively mannose termini.  Hybrid Glycans 
(C) present both mannose termini and GlcNAc termini.  Complex glycans (D) 









ACTIVITY AND EFFECT OF SUBCUTANEOUS TREATMENT WITH THE 
BROAD SPECTRUM ANTIVIRAL LECTIN GRIFFITHSIN IN TWO 
LABORATORY RODENT MODELS1 
INTRODUCTION 
The glycan structures displayed on envelope glycoproteins frequently play 
important roles in virus transmission and entry into target cells [40].  Viruses that 
establish chronic infections, such as HIV and HCV, display a dense shield of 
oligomannose glycans that also assist the pathogen in immune evasion, both 
through the display of “self”-like epitopes as well as by induction of 
immunosuppressive innate immune responses [13, 17, 19, 51, 60]. Antiviral 
compounds that target envelope glycoproteins are classified as “carbohydrate 
binding agents” (CBA), and generally encompass lectins and non-peptidic 
antibiotics such as pradimicin A and –S and benanomicin A (reviewed by 
Balzarini [14]). Several different lectins from natural sources show significant 
antiviral activity in vitro and have been proposed as antiviral prophylactic and 
                                                          
1
 Antimicrob Agents Chemother. 2014 Jan;58(1):120-7. 
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therapeutic compounds.  While there is a plethora of publications in the scientific 
literature showing in vitro antiviral activity of CBA against a broad array of 
enveloped viruses, most in vivo studies on safety and efficacy of this class of 
compounds are in pre-exposure prophylaxis models.  However, two important 
studies demonstrate the potential of antiviral therapy with lectins.  Smee et al. 
[28] demonstrated that post-exposure treatment with the antiviral lectin 
cyanovirin-N, which targets an  α-(1–2)-linked mannobiose substructure on 
oligomannose glycans, showed significant survival benefit 6 hours after infection 
in a murine influenza model. A recent study by Michelow and colleagues [29] 
demonstrated that high dose therapy with human mannose binding lectin (MBL), 
an endogenous C-type lectin that recognizes glycan structures including 
mannose, glucose and fucose on the surface of pathogens, could ameliorate 
Ebola virus infection in a murine model.  Despite their demonstrated antiviral 
activities, the fact that many natural product lectins have significant in vitro and in 
vivo toxicity, acting as non-specific T-cell stimulants and red blood cell 
agglutinating agents, has limited their development as antiviral therapeutics. 
However, not all antiviral lectins are toxins and not all antiviral lectins have cell 
agglutinating activity.  
Griffithsin is a 12.77 kDa red algae derived lectin, that binds the terminal 
mannose residues on the asparagine (N)-linked Man5-9GlcNAc2 structures that 
comprise the vast majority of N-linked glycans in the HIV-1 glycan shield [32, 
163-165]. GRFT displays no human T-cell mitogenic activity, and unlike many 
other lectins does not induce production of pro-inflammatory cytokines in treated 
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human peripheral blood mononuclear cells [35, 169]. In collaborative studies, we 
have shown that GRFT has broad spectrum antiviral activity against HIV-1 [32, 
169, 171], HIV-2 [171], HCV [30, 170], an array of pathogenic coronaviruses, 
including SARS-CoV [172], in addition to influenza A virus, and several other 
enveloped viral pathogens (O’Keefe BR, unpublished).  The in vitro inhibitory 
activity (EC50) of GRFT against HIV-1 is in the mid picomolar to low nanomolar 
range, for most isolates [16, 32, 169]. GRFT has EC50 against HCV (13.9 nM) 
[170] and SARS-CoV (48 nM) [163, 172].  There is a growing body of published 
evidence that GRFT also has antiviral activity ex vivo as well as in vivo:  topical 
application of GRFT prevents HIV-1 infection of human cervical explants [169]; 
intranasal treatments with GRFT prevents disease in mice challenged with 
SARS-CoV [172]; intraperitoneal (IP) treatment with GRFT prevents Japanese 
encephalitis virus infection in mice [173]; and subcutaneous treatment with GRFT 
shows some efficacy against HCV challenge in a mouse-human chimeric liver 
models [30, 170]. The JEV and HCV studies demonstrated that GRFT is 
relatively well tolerated by mice exposed to the drug systemically at 5 mg/kg 
doses, but did not report a comprehensive assessment of GRFT safety as a 
potential systemic antiviral treatment.  Here, we report that minimal toxicity is 
induced by a range of subcutaneous doses of GRFT in two rodent species.  The 
drug was systemically distributed, and accumulates to high levels in the serum 
and plasma after subcutaneous delivery.  Furthermore, we demonstrated that 
serum from GRFT treated animals retained anti-viral activity against HIV-1 
enveloped pseudoviruses in a cell-based neutralization assay. Overall, these 
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findings support further investigation into GRFT’s potential as a systemic antiviral 



















MATERIALS AND METHODS 
Lectin reagents 
Recombinant GRFT was produced in Nicotiana benthamiana plants as described 
previously, purified to >99% purity, and formulated in phosphate buffered saline 
(PBS), pH 7.4 [169]. Phytohemagglutinin A (PHA) was purchased from Sigma. 
Animal housing and care 
6-8 week-old female BALB/c mice (Jackson Laboratory) and Hartley guinea pigs 
(Cavia porcellus, Charles River Laboratories) were housed in a temperature- and 
humidity-controlled room with an alternating light/dark cycle of 12h, with standard 
diet and water ad libitum. All experimental procedures were approved by the 
University of Louisville’s Institutional Animal Care and Use Committee. 
Mouse treatments and sample collection 
To evaluate effects of a single high dose of GRFT, mice were injected 
subcutaneously with 50 mg/kg GRFT (n = 30) or PBS (n = 15).  At 1, 7, and 14 
days post-treatment 10 mice treated with GRFT and 5 control animals were 
sacrificed and blood was collected by cardiac puncture. Kidneys, livers, and 
spleens were excised. For chronic administration, mice were treated with 10 
mg/kg GRFT (n = 15) or PBS (n = 15) daily for 14 days.  Each group was further 
subdivided into 3 groups of 5 mice each.  Blood was collected from the 
submandibular vein every other day, alternating between subgroups. Animals 
were sacrificed on day 14 (9 mice per treatment group), day 16 and day 21 (3 
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mice per treatment group at each time point), and the samples collected as 
outlined above. 
Guinea pig treatment and sample collection 
For chronic administration in guinea pigs, two studies were conducted at different 
times.  In the first experiment, 10 mg/kg GRFT (n=12) or 1 ml/kg PBS (n=6) was 
subcutaneously administered daily for 10 days. The second experiment was 
similar to the first, except for the number of animals (GRFT, n=10; PBS, n=6). 
Half of the animals in each group were sacrificed on day 11 after cardiac 
puncture exsanguination under isoflurane anesthesia, and the remaining animals 
were euthanized on day 15.  Blood and organs were collected at sacrifice.  
Extraction of GRFT from mouse organs 
100-500 mg pooled organ tissues were homogenized in 1 ml PBS supplemented 
with complete, EDTA-free Protease Inhibitor Cocktail (Roche) and the samples 
cleared by a series of two centrifugations steps at respectively 10,000 and 
15,000 x g for 10 min each. The supernatants were stored at - 20˚C until use.   
GRFT capture immunoassay using the HIV-1 envelope glycoprotein gp120 
To detect trace amounts of GRFT present in serum and plasma, and in 
homogenized organ tissues, we used a HIV-1 gp120 binding ELISA as previously 
described [35] with a few modifications.  Briefly, Maxisorp plates (Nunc) were 
coated with 25 ng purified gp120 (Protein Sciences) and incubated overnight at 
4oC.  Plates were blocked with 3% (w/v) Bovine Serum Albumin (BSA) in PBS 
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containing 0.05% Tween 20 (PBS-T).  Samples were diluted 1:10 in blocking 
buffer and were incubated at RT for 1 hour.  Serial dilutions of purified GRFT 
were run in parallel to generate a standard curve.  The gp120-bound GRFT was 
detected by rabbit anti-GRFT antiserum (1:25,000) followed by HRP-conjugated 
goat anti-rabbit IgG (1:10,000).  Plates were developed with SureBlue TMB 
Microwell Peroxidase Substrate, and reactions were stopped with 1N H2SO4.  
Absorbance readings at 450 nm and 570 nm were measured using a BioTek 
Synergy HT plate reader. 
Evaluation of Anti-HIV Activity.   
HIV-1 neutralization activity of heat-inactivated serum or plasma was measured 
using pseudovirus neutralization assays as previously described [174]. Briefly, 
molecularly cloned DU156 env-pseudotyped virus particles were generated by 
transfection of 293T cells and titrated in TZM-bl cells.  Antiviral activity was 
measured as a function of luciferase reporter gene activity. ID50 values were 
defined as the sample dilution required to reduce luminescence by 50% in 
comparison to wells with no sample added (within the linear range of the assay).  
Hematology parameters and Serum Chemistry.   
A complete blood count (CBC) was run for guinea pig samples using a 
Hemavet® 950 (Drew Scientific) standardized for guinea pig blood. The following 
parameters were quantified in potassium-EDTA anticoagulated whole blood: red 
blood cells (RBC; 104/µl), total and differential leukocyte count (neutrophils, 
lymphocytes, monocytes, eosinophils, and basophils as 103/µl or %), hemoglobin 
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concentration (HGB; g/dl), hematocrit (HCT; %), mean corpuscular volume 
(MCV; fl), mean cell hemoglobin (MCH; pg), mean cell hemoglobin concentration 
(MCHC; g/dl), red cell distribution width (RDW; %), platelets (PLT; 104/µl), and 
mean platelet volume (MPV; fl). 
In the first guinea pig experiment levels of the following serum chemistries  were 
assessed and  the differences analyzed by two-way ANOVA: serum albumin 
(Alb), alkaline phosphatase (ALKP), amylase (Amy), alanine aminotransferase 
(ALT), blood urea nitrogen (BUN), calcium (Ca), cholesterol (Chol), creatinine 
(Creat), globulin (Glob), glucose (Glu), phosphorus (Phos), total bilirubin (TBil), 
and total protein (TP). Based on the results obtained, we decided to further 
measure the effect of GRFT on selected markers including serum albumin, 
alkaline phosphatase, and amylase  in the second experiment using a VetTest® 
Chemistry Analyzer (IDEXX Laboratories)  
Hemagluttination assays.   
Guinea pig, sheep, and human blood (Innovative Research), and blood collected 
from untreated mice was washed and resuspended at a final concentration of 1-
2% (v/v) in 1X PBS containing 3 g/L BSA and 1 g/L sodium azide.  PBS, PHA, or 
GRFT were mixed with an equal volume of erythrocytes in a 96-well round 
bottom plate. The plate was incubated for 1 hr at RT, followed by overnight 
incubation at 4°C.  Finally, wells were dried and hemagglutination activity was 




Statistical Analysis.  
Statistical analysis was conducted using Graph Pad Prism 5 and SAS software 
version 9.3.  Because of the stratification by guinea pig study, day of sacrifice 
and treatment group, it was decided to increase statistical power by using all the 
data from both studies.  Three-way ANOVA [175] analysis was utilized, which 
allowed testing for treatment effect while at the same time adjusting for 
differences between the two studies and the days of sacrifice. For initial 
univariable analysis, the two-sample t-test [176] or Wilcoxon rank sum test [177] 
was used to test for differences between study, day of sacrifice, and treatment.  
For data sets collected in only one guinea pig study – such as weight change and 
non-selected serum chemistries, a two-way ANOVA was utilized. A p-value < 












Griffithsin serum concentrations.   
Plasma samples collected from mice injected with a single high dose of 50 mg/kg 
GRFT showed up to 4 nM GRFT (4 nM equals 51.08 ng/ml) in animals sacrificed 
one day post treatment (Figure 2.1A).  These levels decreased considerably to 
less than 0.5 nM by day 7, and persisted through day 14. 
In chronically dosed mice, plasma concentrations of GRFT peaked at 25 nM 
(Figure 2.1B) by day 11, followed by a gradual decrease in detectable GRFT 
even with subsequent treatments. This trend continued throughout the recovery 
time. Notably, concentrations of GRFT persisted in the plasma at levels of 
approximately 4 nM after a week of recovery (Figure 2.1B).  GRFT 
concentrations in sera from chronically treated guinea pigs were similar to that of 
chronically treated mice, with mean concentrations of 36 nM at day 11 and 11.36 
nM at day 15 (Figure 2.1C).   
Anti-HIV Activity of plasma and serum.   
Plasma samples collected from mice treated with a single dose of 50 mg/kg 
GRFT neutralized HIV-1 pseudoviruses (Clade C primary sexually transmitted 
isolate Du156) with a mean ID50 (dilution required for a 50% reduction in 
luminescence versus controls) of 1500 on experimental day 2 (Figure 2.2A).  
This neutralization activity decreased in samples obtained at days 8 (ID50 of 300) 
and 15 (ID50 of 200). Plasma from chronically treated mice neutralized the HIV-1 
Du156 pseudovirus with an ID50 value of approximately 800 (Figure 2.2B) at day 
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14.  After the 7 day recovery period, the ID50 values decreased to approximately 
200.   Serum samples collected from guinea pigs after chronic treatment with 10 
mg/kg GRFT displayed a mean ID50 of approximately 3277 at day 11 and 576 at 
day 15, respectively.   The HIV-1 Du156 neutralization activity of guinea pig sera 
correlated well with the concentration of GRFT detected in the serum; however, 
the GRFT serum concentrations detected in mouse samples predicted only about 
14-25% of the actual serum HIV-1 neutralization activity we observed, confirming 
that additional non-specific HIV-1 neutralizing activities in mouse serum 
contribute to the higher-than expected overall HIV-1 inhibitory activity in the 
mouse sera.  
GRFT distribution into tissues. 
Organs from mice chronically treated with GRFT were harvested, and total 
protein extracted.  We measured the total amounts of GRFT that accumulated in 
these tissues by gp120 binding ELISA.  Figure 2.3 shows that GRFT 
accumulated in all three organs assayed, with most GRFT accumulating in the 
spleen.  Non quantitative immunofluorescence studies detected GRFT in the 
same organs (liver, kidney and spleen) harvested from treated guinea pigs (data 
not shown). 
GRFT is tolerated after subcutaneous administration 
We studied the toxicity of GRFT in guinea pigs using several parameters 
including mortality, behavior, animal body and organ weight changes, tissue 
pathology, and changes in blood properties. 
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All animals survived and no change in behavior was observed.  Since the guinea 
pigs used in this work were juvenile, we evaluated their overall fitness after 
GRFT treatment using body weight as a surrogate marker. Animals were 
weighed at day 1 and at time of sacrifice. Using a 2-way ANOVA to measure the 
impact of treatment and time on bodyweight gains, we found that GRFT 
treatment resulted in significantly less bodyweight gain in comparison with PBS 
treated controls (p=0.0011, Figure 2.4) 
Liver, kidney, and spleen weights measured at termination were normalized to 
total body weights and compared to time matched controls. A statistically 
significant increase of the normalized weights of guinea pig livers and spleens 
was observed for GRFT treated animals (p=0.008 and 0.005, respectively, Figure 
2.5).  Tissue sections from guinea pigs in the second experiment were stained 
with hematoxylin and eosin and evaluated in a blinded fashion by a veterinary 
pathologist (O.F.).  No distinct pathologies were observed as a result of GRFT 
treatment.  Of all CBC parameters tested, a statistically significant difference was 
observed only in Red Blood Cell Width (RDW) (p=0.016, Table 2.1).  Of note the 
RDW values obtained for GRFT-treated animals were still within the normal 
physiological range described for guinea pigs (38).  
In addition to CBCs, serum chemistries were examined. When data collected 
from both experiments were combined for analysis, a statistically significant 
increase was observed for Alkaline Phosphatase after GRFT treatment 
compared with controls (p=0.001, Figure 2.6). There were no statistically 
significant differences between the GRFT treated group and the PBS control 
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group in the remaining serum chemistry when examined by 2-way ANOVA 
(Figure 2.6).  
Since many natural product lectins cause hemagglutination, we investigated 
GRFT’s hemagglutination activity in several species. Blood samples from guinea 
pig, mouse, sheep, and human were tested. Interestingly, only red blood cells 
from guinea pigs were affected by GRFT—at concentrations over 5 µg/ml (Fig. 
2.7).  As expected, the vehicle (PBS) did not show any hemagglutination activity 
on erythrocytes, and the known hemagglutinating agent PHA demonstrated 














In this study, we demonstrate that GRFT persists in serum and plasma of 
laboratory rodents at concentrations well above the EC50 described for several 
known enveloped viruses [23, 32, 170, 178] after subcutaneous administration. 
Although decreasing in concentrations after final administration, functionally 
active concentrations of GRFT, as determined by gp120 binding ELISA, remain 
in circulation for many days after treatment cessation both in single and chronic 
dosing regimens.  These findings support further investigations of the utility of 
GRFT in treatment of both acute and chronic viral infections.   
Every drug candidate must show a favorable safety profile to advocate for 
its further development. Previously, we demonstrated that GRFT was devoid of 
any mitogenic and cytotoxic activity, was unable to induce cell mediators of 
inflammation, and had only minimal off target effects on human cells [35] 
corroborating with other works [32, 169] and unlike other anti-HIV lectins 
including CVN and ConA [149, 179]. In the present in vivo studies GRFT did not 
alter experimental animal behavior and no animal died as a result of treatment. 
Using juvenile animals, we did notice that guinea pigs treated with GRFT gained 
weight significantly slower than those injected with PBS. This is not the case 
when adult mice are treated s.c. with GRFT (manuscript in preparation). Organ 
toxicity was also assessed both by measuring weights and histopathology. While 
liver and spleen percentages displayed a statistically significant increase in 
comparison with controls, histopathological examination of the organs from 
GRFT treated animals did not show any pathology.  
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When a complete blood count was performed and serum chemistries 
analyzed, we observed that most of the parameters were not significantly 
changed as a result of GRFT treatment. The only exception was RDW.  Although 
significantly different from PBS controls, RDW values obtained from GRFT-
treated animals remained within the normal range described for guinea pigs. In 
serum chemistries, alkaline phosphatase was significantly elevated in GRFT 
treated guinea pigs.  Whether this elevation is related to the increased liver mass 
to body weight ratio seen with GRFT-treated animals is yet to be determined 
since the alkaline phosphatase isotype was not determined.  
As a xenogeneic protein, a key concern is a possible immune response to 
GRFT which could lead to anaphylaxis [180]. Our data showing treatment 
associated increases in spleen and liver mass to body weight ratios is suggestive 
of a nascent immune response to GRFT treatment. However, we were unable to 
detect anti-GRFT antibodies in sera from these treated animals, probably 
reflective of the short duration of these studies.  Although GRFT is a relatively 
weak immunogen, we are able to raise high titer antibodies in animals immunized 
with GRFT in the presence of adjuvant; these hyperimmune sera are binding, but 
non-neutralizing (data not shown).  Immunogenicity of biologic drugs is a widely 
acknowledged issue, and our data suggest that future efforts to de-immunize 
GRFT by structure-guided elimination of T-cell epitopes [161, 162], may be 
necessary before the product is used for chronic treatment of viral infection in 
humans. Lectins are well known for their mitogenic and agglutinating properties 
[149, 151, 179, 181-183] which prevent their use as therapeutics. We have 
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addressed the mitogenicity concern by showing previously that GRFT lacks T-
cell mitogenic activity [35]. Here, we demonstrated that GRFT does not 
agglutinate red blood cells from several species including human, mouse and 
sheep. However, we observed that guinea pig erythrocytes were agglutinated by 
GRFT at high concentrations. The cause of this discrepancy is unclear, but may 
well be associated with the treatment-associated increase in red blood cell width 
we observed.  We conclude that the preliminary toxicity profile of GRFT is 
acceptable and favors its further development in antiviral prophylaxis and 
therapy. 
GRFT is currently under development as a topical microbicide as well as a 
broad spectrum antiviral. However GRFT is not systemically bioavailable after 
topical administration (our unpublished observations), so parenteral 
administration is probably necessary to achieve sufficient drug in systemic 
concentrations necessary for effective suppression of viral replication.   Our data 
confirm that subcutaneous  administration of  GRFT is a viable and efficient way 
to get the drug into circulation to allow a sustained pharmacodynamic effect 
[184].  Our data support the results of published studies on GRFT prophylactic 
efficacy in murine models of HCV and JEV infection[30, 31, 173].  Both studies 
found that GRFT effectively suppressed viral replication when administered at a 
5 mg/kg dose, either subcutaneously or intraperitoneally. We are currently 
studying whether administrations of GRFT, under the 10 mg/kg dosage, are 
sufficient to maintain drug concentrations at potentially therapeutic levels. There 
is substantial precedent for patient self-administration of drugs via the 
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subcutaneous route; indeed the peptide HIV fusion inhibitor Enfurtide (T-20) is 
dosed in this fashion.  Our data confirm that we can achieve HIV-1 Du156 50% 
serum neutralization indices in excess of 500 after 14 daily doses of GRFT at 10 
mg/kg (Fig. 2.2), which should be sufficient to inhibit HIV replication, and perhaps 
promote viral evolution towards enhanced humoral antibody suppression[14, 
151, 184].  These levels were also more than sufficient to prevent JEV and HCV 
infection in respective mouse models [16, 31] 
Under selection pressure with CBA, susceptible viruses may evolve 
towards resistance through loss of key N-linked glycosylation sites [25, 185-188]. 
Interestingly, in the case of HIV-1, CBA resistance correlates with reduced viral 
fitness and enhanced susceptibility to neutralizing antisera [14, 186, 188]. 
Consequently, it has been suggested that CBA therapy of chronic viral infections 
like HIV-1 and HCV may promote viral evolution towards resistance to the CBA 
concomitant with enhanced susceptibility to host immune control.  This concept 
of CBA-mediated immunotherapy holds considerable appeal as a method to 
promote durable immune control, and perhaps even eradication of HIV infection 
[14]. Given GRFT’s antiviral activity in the mid picomolar range, and our data 
here that show that the drug accumulates to relevant therapeutic concentrations 
which are tolerated with minimal toxicity, GRFT is a strong candidate for further 
experimental testing of this idea first put forward by Dr. Balzarini and colleagues 





Figure 2.1 Griffithsin concentrations in plasma and serum samples.  Data were 
obtained from mouse plasma after a single high-dose administration of 50 mg/kg 
GRFT (A), a chronic daily administration of 10 mg/kg GRFT (B), and from guinea 
pig serum after 10 daily administrations of 10mg/kg GRFT (C).  PBS was 






Figure 2.2.  Antiviral activity of samples collected from GRFT treated animals. 
HIV-1 env- pseudovirus neutralization activity was assessed for mouse plasma 
after a single high dose administration of 50 mg/kg GRFT (A) and expressed as 
ID50.  The ID50 values were obtained for samples from guinea pigs and mice 
chronically treated with 10mg/kg GRFT (B). Control animals were treated with 
PBS bars indicate mean group concentration. 1-way ANOVA significance 




Figure 2.3. Quantitation of GRFT in mouse organs.  Pooled Protein samples 
were extracted from kidneys, livers, and spleens after a chronic subcutaneous 





Figure 2.4. Guinea pig body weight gain as an indicator of overall health.  Body 
weights were measured on experimental Day 1 and on the termination day (Day 






Figure 2.5. GRFT does not affect guinea pig organ weights. Liver (A), kidney (B), 





















k/µl 4.92 ± 2.43 2.15 ± 0.23 4.35 ± 1.28 2.90 ± 1.36 
 NE k/µl 2.30 ± 1.46 0.96 ± 0.13 1.67 ± 0.45 1.01 ± 0.42 
 LY k/µl 2.49 ± 1.11 1.14 ± 0.28 2.60 ± 0.89 1.82 ± 0.99 
 MO k/µl 0.09 ± 0.10 0.03 ± 0.03 0.07 ± 0.03 0.06 ± 0.04 
 EO k/µl 0.03 ± 0.02 0.02 ± 0.01 0.02 ± 0.01 0.01 ± 0.02 




M/µl 4.30 ± 0.06 4.12 ± 0.18 4.75 ± 0.21 4.37 ± 0.22 
 Hb g/dl 12.23 ± 0.64 11.64 ± 0.46 13.10 ± 0.46 12.22 ± 0.61 
 HCT % 38.30 ± 2.31 36.12 ± 1.47 41.57 ± 1.76 39.52 ± 1.94 
 MCV FL 88.97 ± 4.73 87.58 ± 1.29 87.53 ± 1.70 90.40 ± 0.52* 
 MCH pg 28.43 ± 1.33 28.26 ± 1.52 27.63 ± 0.61 27.96 ± 1.04 
 MCHC g/dl 31.97 ± 0.25 32.26 ± 1.33 31.50 ± 0.26 30.94 ± 1.11 




k/µl 595.33 ± 54.31 628.60 ± 44.77 677.33 ± 11.93 659.00 ± 34.26 
 MPV fL 4.40 ± 1.14 3.92 ± 0.23 3.57 ± 0.12 3.84 ± 0.24 
 
Table 2.1.  Hematological profile for guinea pigs after chronic treatment with 
GRFT. Data represent the mean values +/- standard deviation for white blood 
cells (WBC), neutrophils (NE), lymphocytes (LY), monocytes (MO), eosinophils 
(EO), basophils (BA) , red blood cells (RBC), hemoglobin (Hb), hematocrit (HCT), 
mean corpuscular volume (MCV), mean cell hemoglobin (MCH), mean cell 
hemoglobin concentration (MCHC), red cell distribution width (RDW), platelets 










Figure 2.6. Serum chemistry data for guinea pigs after chronic treatment with 
GRFT.  Levels of Serum Albumin (A), Alkaline Phosphatase (B), and Amylase 
(C) were obtained from GRFT or PBS treated animals at sacrifice.  Bars indicate 





Figure 2.7. Hemaggluttination activity of GRFT.  A wide range of GRFT 
concentrations (5 µg/ml equals 391 nM) was used to examine GRFT’s potential 
hemagluttination activity on erythrocytes from multiple species including sheep 
(A),  Guinea pig (B), Human (C), and  Mouse (D).  PHA (5 µg/ml) and PBS were 













 THE PHARMACOKINETCIS OF THE ANTIVIRAL LECTING GRIFFITHSIN 
INDICATED MULTIPLE POTENTIAL USES AND CHALLENGES  
INTRODUCTION 
Various lectins, carbohydrate binding proteins that bind specific glycan 
structures, are important components of many organisms’ innate pathogen 
defense system.  Several lectins isolated from natural sources are known to 
inhibit microbial and viral infections in vitro and in vivo [29, 31, 37, 142, 189, 190].  
Griffithsin, derived from the red alga Griffithsia, is a dimeric lectin with a total of 6 
binding sites capable of binding terminal oligomannose residues on asparagine 
(N)-linked Man5-9GlcNAc2 structures[32, 163-166].  Mannose terminal glycan 
structures appear to comprise a significantly greater proportion of glycans on 
pathogen surfaces than in mammalian host cells.  In fact, oligomannose 
structures comprise the vast majority of N-linked glycans in the HIV-1 glycan 
shield [13, 60], where they assist in the virus’s evasion of immune surveillance 
[40].  Multiple studies have described Griffithsin’s HIV-1 neutralization EC50 in 
vitro as being within the mid picomolar range [16, 32, 169].  GRFT also exhibits 
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nanomolar activity against several other enveloped viruses such as HCV, HSV-2, 
SARS CoV, and JEV, amongst others[23, 31, 36, 173].  GRFT prevents viral 
infection in vitro by binding the envelope oligomannose glycans, and thereby 
occluding functionally important domains of the viral envelope protein, preventing 
interactions with cell-surface receptors, or otherwise impeding structural 
transitions necessary to effect infection.  In the case of HSV-2, GRFT may also 
act by inhibiting virus egress and spread post-infection[36].  Topical application of 
GRFT prevents HIV-1 infection of human cervical explants [169], and inhibits 
viral spread in murine HSV-2 vaginal challenge[36].   
In preexposure prophylaxis models, GRFT has displayed antiviral activity 
against HSV-2, SARS-CoV, and HCV [23, 31, 36, 171, 191].    In examining 
GRFT’s systemic chemotherapeutic potential, our previous studies  have shown 
that in two rodent models, GRFT is tolerable in short term subcutaneous dosing, 
while retaining anti-viral activity in serum [34].  This tolerability profile, retained 
antiviral activity, and broad spectrum activity against susceptible viruses further 
supports the study of GRFT as a systemic chemopreventative or 
chemotherapeutic. 
While GRFT has initially been evaluated as a potential topical microbicide, 
its pharmacokinetic profile – which could limit its practical utility as 
chemotherapeutic or chemopreventative - is currently unknown.  Given GRFT’s 
observed resistance to low pH and a number of proteases[192], we hypothesized 
that GRFT may have some degree of oral bioavailability. We compared the 
concentration of GRFT in serum from treated animals following intravenous, 
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subcutaneous, and oral dosing, and report that the pharmacokinetic profile of 
GRFT can vary greatly depending on method of administration.   Additionally, we 
report a small fraction of oral dosage of GRFT formulated in PBS passes through 
the digestive tract and retains anti-viral activity in fecal material.  Further, we 
found that after both single dose and 10 day chronic oral administration, GRFT 
was undetectable in serum and urine, indicating that GRFT is either not 
systemically absorbed to a detectible degree upon ingestion or inactivated during 
the absorption process.  Accordingly, the method of administration should be 
considered when researching the usage of GRFT as an orally dosed pre-
exposure prophylactic, or intravenously or subcutaneously-dosed systemic 















MATERIALS AND METHODS 
Lectin reagents 
Recombinant GRFT produced in Nicotiana benthamiana plants as 
described previously [169]  was purified to >99% purity in phosphate buffered 
saline (PBS), pH 7.4 with less than 0.05 Endotoxin Units (EU) per milligram. 
Animal housing and care 
250g Sprague Dawley Rats (Rattus norvegicus, Charles River 
Laboratories) were housed in a temperature- and humidity-controlled room with 
an alternating light/dark cycle of 12h, with standard diet and water ad libitum. All 
animal procedures were approved by the University of Louisville’s Institutional 
Animal Care and Use Committee. 
Pharmacokinetic Study Dosing and Sample Collection 
250g Sprague Dawley rats were procured from Charles River with 
indwelling femoral vein catheter.  Rats were weighed and treated with a single 
dose of either 10mg/kg or 20mg/kg GRFT.  For intravenous treatment, indwelling 
catheters were checked for patency and either 10mg/kg or 20mg/kg GRFT was 
infused into the catheter over a 15 second period.  Catheters were then flushed 
by PBS infusion of 3 times the catheter volume and filled with heparinized 
glycerol (Braintree Scientific) before reinsertion of the catheter plug.  For 
subcutaneous treatment, 10 mg/kg or 20 mg/kg GRFT was injected under the 
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skin between shoulders.  For oral dosing treatment, 2.5 mg of GRFT formulated 
to a final volume of 1 ml was dosed via gastric lavage. 
In intravenously and subcutaneously dosed animals, approximately 150 µl 
of blood was drawn via indwelling femoral catheter at the following time points 
after GRFT administration: 15 minutes, 30 minutes, 1 hour, 2 hour, 4 hour, 8 
hour, 24 hour, and 48 hours (sacrifice).  To capture later time points, an 
additional cohort of animals had 150ul blood drawn at 72 and 96 hours post 
dosage.  Orally dosed animals had 150µl of blood drawn at the following time 
points post administration: 10 minutes, 20 minutes, 30 minutes, 1 hour, 2 hours, 
4 hours, 6 hours, 24 hours and 24 hours.  All animals were sacrificed by CO2 
asphyxiation followed by thoracotomy at the conclusion of the study. 
Chronic Oral Dosing Treatment and Sample Collection 
18 rats were treated daily with either 1ml PBS (n=6), 5 mg GRFT (n=6, 1 
ml dosing volume), or 10 mg GRFT (n=6, 1 ml dosing volume) for a period of 10 
days via gastric lavage.  On treatment day 5, blood samples were drawn via 
lateral tail vein approximately 3 hours after oral dosing.  On day 10, animals were 
treated, and approximately 3 hours after treatment, animals were sacrificed via 
CO2 asphyxiation followed by thoracotomy.  Blood was drawn by cardiac 
puncture after euthanasia.  Urine was taken at selected time points after oral 




Active Mass Balance Rat Treatment and Sample Collection. 
10 rats were treated with a single dose of either 2.5 mg GRFT (10mg/ml) 
through either intravenous indwelling catheter or subcutaneous dose.  5 rats 
were treated with 2.5 mg of GRFT (1 ml dosing volume) via gastric gavage.   
Post dosage, animals were placed in metabolic cages and urine was collected at 
the following time points after treatment: 4 hours, 8 hours, 12 hours, 20 hours, 
and 48 hours. Fecal pellets were collected at 24 and 48 hours. Urine volume and 
fecal pellet mass was quantitated for mass balance calculation. 
Fecal Pellet Collection and Extract preparation – Chronic Oral Treatment 
Fecal pellets from treated animals were obtained at 8 and 24 hours after 
initial treatment and at selected days thereafter by randomly drawing 6 dried 
pellets from animal cage bedding.  Briefly, for fresh fecal pellets not requiring 
additional PBS for rehydration, 1ml of PBS was added per 1 gram of pellets in a 
1.5ml Eppendorf tube.  For dried fecal pellets requiring rehydration 2ml of PBS 
per were added per 1 gram of pellets in an Eppendorf tube.  Pellets were allowed 
to absorb the PBS for 15-30 minutes before crushing and mixing.  After crushing 
and mixing, the resulting fecal slurry was centrifuged at 1000g for 5 minutes and 
supernatant removed.  Supernatant was spun again to pellet and remove and 
debris and final extract supernatant was removed and aliquoted for GRFT 
concentration determination and anti-HIV activity testing.  Fecal extract samples 
were pooled by combining equal volumes of extract from each cage within the 
applicable treatment group. 
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          Fecal pellet extracts from chronically treated animals underwent additional 
processing to further remove contaminants before HIV-1 pseudovirus 
neutralization assays.  Samples were sterilized and filtered using Costar Spin-X 
centrifuge Tube Filters with a 0.22 µm Cellulose acetate filter.  After filtration, 
samples were then dialyzed in a dialysis cassette with a 2000 molecular weight 
cut off membrane in PBS for 24 hours at 4ºC. 
Extracts for mass balance experiments were prepared by desiccation and 
rehydration of fecal pellets.  After overnight desiccation in a vacuum centrifuge, 
pellets were pulverized into powder using a commercial coffee grinder.  Pellet 
extracts were formulated using 0.5g of dried powder and 2 ml of PBS. After 
rehydration the resulting fecal slurry was thoroughly mixed and centrifuged at 
1000g for 5 minutes and supernatant removed.  Supernatant was spun again to 
pellet and remove and debris and final extract supernatant was removed and 
aliquoted for GRFT concentration determination. 
GRFT capture immunoassay using the Influenza HA 
To detect trace amounts of GRFT present in serum and fecal extracts, we 
used an ELISA as previously described with modifications [34].  Briefly, Maxisorp 
plates (Nunc) were coated with 10 µg/ml purified influenza hemagglutinin (HA) in 
PBS (Kentucky Bioprocessing) and incubated overnight at 4oC.  Plates were 
blocked with ~2.5% (w/v) Bovine Serum Albumin (BSA) in PBS containing 0.05% 
Tween 20 (PBS-T).  Samples were diluted in blocking buffer and were incubated 
for 1 hour at RT.  Serial dilutions of purified GRFT were run in parallel for 
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standard curve generation.  Active, HA-bound GRFT was detected by rabbit anti-
GRFT antiserum (1:25,000) followed by HRP-conjugated goat anti-rabbit IgG 
(1:10,000).  Plates were developed with SureBlue TMB Microwell Peroxidase 
Substrate, and reactions were stopped with 1N H2SO4.  Absorbance readings 
were measured at 450 nm and 570 nm using a BioTek Synergy HT plate reader. 
Evaluation of Anti-HIV Activity of Fecal Extracts.   
HIV-1 neutralization activity of fecal pellet extracts from pooled, chronically 
treated animals was measured using pseudovirus neutralization assays as 
previously described [174]. Briefly, DU156 env-pseudotyped virus particles were 
generated by transfection of 293T cells and titrated in TZM-bl cells.  Antiviral 
activity, a function of luciferase reporter gene activity, was determined by relative 
luminescence after addition of substrate. ID50 values were defined as the sample 
dilution required to reduce luminescence by 50% in comparison to wells with no 
sample added.  
Histopathology   
Hematoxylin and eosin stained tissue slides were examined in a blinded 
manner by a veterinary pathologist (M.P.) for gross or cellular abnormalities.   
Pharmacokinetic Analysis 
Pharmacokinetic Parameters were analyzed using PK Solutions Software 
(Summit PK). Parameters were determined using GRFT serum concentrations at 
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sampling time points.   Values were generated from time vs. concentration 
curves based upon amount of GRFT dosed/gram bodyweight.  Values generated 
included Absorption, distribution, and elimination half-lives, area under the curve 


















GRFT was detectible at all time points tested - including up to 96 hours 
post dose (Figure 3.1).  15 minutes post intravenous administration, animals 
displayed an average serum concentration of approximately 74 µg/ml and 141 
µg/ml based on initial doses of 10 mg/kg and 20 mg/kg respectively.  By 8 hours 
after administration, serum concentrations had decreased to average 
concentrations 897 ng/ml (10mg/kg dosage) and 1540 ng/ml (20 mg/kg dosage) 
(Figure 3.1A).  Analysis of elimination curves by Pk Solutions software revealed a 
multiphasic elimination, with 3 distinct phases observed.    Early phase 
elimination kinetics (0-2 hrs) revealed an absorption half-life of approximately 0.5 
hours, with late phase elimination half-life ranging from 10 to 17 hours (Table 
3.1).  GRFT remained detectible in serum at low ng/ml concentrations up to 96 
hours post intravenous treatment (Figure 3.1B). 
Pharmacokinetics - Subcutaneous Dosing 
After subcutaneous administration, GRFT displayed increasing serum 
concentrations, reaching peak serum concentration approximately 4 hours post 
subcutaneous administration (Figure 3.1A).  Thereafter GRFT concentrations 
decreased at rates analogous to those seen in intravenously dosed animals.  At 
10mg/ml, GRFT displayed a Cmax of 6.6 µg/ml whereas at 20 mg/ml GRFT 
displayed a mean Cmax of 19.7 µg/ml.  GRFT remained detectible in serum at low 
ng/ml concentrations up to 96 hours post subcutaneous treatment. 
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Pharmacokinetics - Oral Dosing 
GRFT did not display any detectible serum concentrations at any time 
point tested after oral administration.   
 
Chronic GRFT oral treatment  
           Serum collected from rats orally dosed daily with PBS, 5 mg GRFT and 
10mg GRFT did not display detectible GRFT concentrations on either day 5 or 
day 10.  Urine samples obtained from these rats also failed to display detectible 
GRFT concentrations. 
 
Fecal GRFT concentrations -Chronic Dosing 
Fecal extracts from fresh fecal pellets displayed low concentrations of 
GRFT.  At 8 hours after initial dosing, animals treated with 5 mg and 10 mg 
GRFT displayed an average fecal GRFT extract concentration of approximately 2 
nM (Figure 3.2A).  However, average GRFT concentration of both groups 
decreased at 24hr after dosing, with fecal extracts from animals treated with 5mg 
GRFT displaying an average concentration of 0.5 nM while animals treated with 
10 mg GRFT displayed an average concentration of 0.75 nM. (Figure 3.2B). 
Fecal extracts from random pellet draws also displayed varying amounts of 
GRFT.   Dessicated fecal pellet extracts drawn on days 2, 3, 8 and 9 were 
analyzed.  As expected, none of the fecal pellet extracts from PBS treated 
animals displayed GRFT concentrations (Figure 3.2C).  Fecal pellet extracts from 
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animals treated with 5mg GRFT ranged from 1.7 nM to 20 nM.  Fecal pellet 
extracts from animals treated with 10 mg GRFT ranged from 1.7 nM to 126 nM.   
HIV-1 Neutralization activity Fecal Pellect Extracts of Chronically treated animals. 
          Pooled fecal extracts from rats treated with 5mg and 10mg GRFT 
neutralized HIV-1 pseudoviruses (Clade C primary sexually transmitted isolate 
Du156) with an ID50 of 590 on experimental day 3 for those animals treated with 
5mg GRFT and an ID50 of 2059 for animals treated with 10 mg GRFT (Figure 
3.3).  This neutralization activity was also observed in samples obtained at later 
time points.  On treatment day 8 sera from animals receiving a dosage of 5mg 
GRFT had an ID50 of 885 while those receiving 10 mg had an ID50 of 9452 (Figure 
3.3).  On treatment day 9 fecal pellet extracts had ID50s of 2195 and 13307 for 
groups receiving 5mg/kg and 10mg/kg GRFT respectively (Figure 3.3).   
Mass Balance of Active GRFT  
Active concentrations of GRFT were detected in urine or fecal material 
produced during the first 24 hours following intravenous, subcutaneous and oral 
dosage of 2.5 mg GRFT.  After intravenous administration and subcutaneous 
administration, GRFT was detected in urine (Figure 3.4).  After intravenous 
administration of 2.5 mg GRFT, approximately 131 µg of active GRFT was 
recovered, whereas 41 µg of active GRFT was recovered from subcutaneously 
treated animals.  However, a different elimination profile was observed following 
oral administration.   Following oral administration, approximately 2.3 µg GRFT 
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was recovered from fecal material.  GRFT was not detectible in urine at any time 
point tested in orally dosed animals.  
Histology 
Organ slides did not reveal any treatment-related pathologies.  However 

















 The pharmacokinetics data we derived here expand upon our previous 
studies (Barton et al.), which showed that subcutaneous treatment with 10 mg/kg 
GRFT was well tolerated in two laboratory rodent species (mice and guinea 
pigs), and accumulated to therapeutically relevant levels – above GRFT’s anti-
HIV EC50 of 40 pM. Here we show in rats, a standard rodent model used for PK 
studies, that GRFT has a complex PK profile which may prove important in 
designing future studies.     
As seen in Figure 3.1, GRFT displays different drug concentration curves 
depending upon method of administration.  Intravenously-dosed GRFT exhibits a 
multiphasic elimination pattern, with the serum half-life changing over the 
observation period.  While the majority of a single dose of GRFT is eliminated 
within 8 hours of treatment, potentially therapeutic concentrations above GRFT’s 
anti-HIV-1 EC50 remain for at least 96 hours post administration.  This complex 
elimination pattern, which can vary among other protein based pharmaceuticals 
in time to maximum serum concentrations and rates of elimination [193-195], 
may represent multiple processes going on simultaneously.  These may include 
continual absorption, degradation, protein binding, and elimination processes. 
GRFT was observed to be renally excreted in urine in substantial quantities 
shortly after dosing intravenous dosing.  However, this amount was also 
observed to decrease over time.  Further, prior research within our lab has 
detected GRFT in vaginal mucous after subcutaneous dosing (observational 
studies).  Thus, it is possible that GRFT could still be distributing more 
63 
 
extensively into deeper physiological compartments while other fractions of 
GRFT are being eliminated. This speculation will require in vivo radiolabeling 
studies of GRFT for a full determination as to GRFT’s ultimate fate. Further, it is 
also possible that degradative proteolysis is occurring.  While previous studies 
have shown GRFT is relatively proteolytically resistant to many proteases, it has 
been reported that GRFT is susceptible to leukocyte elastase [192]. Thus it is 
possible that GRFT is vulnerable to some other unknown proteases as well. This 
possibility will require both extensive in vitro protease degradation testing as well 
as examination of degradation products in serum after systemic administration 
using radiolabeled GRFT to determine whether GRFT is being degraded or 
retained within the system. 
 The final phase of elimination of GRFT appears to be substantially longer 
than the initial elimination phases.  This persistence is comparable to other 
protein therapeutics, such as monoclonal antibodies, which also present long 
serum persistence[194] as well as smaller molecule biologics, such as 
recombinant epoetin[193]—though recombinant epoetin concentrations have 
been observed to be eliminated within two to three days after intravenous dosing 
[188]. This serum persistence could potentially be from redistribution of GRFT 
from deeper physiological compartments and mucosal surfaces.  However, it is 
also very possible, if not likely, that these low residual concentrations of GRFT 
are interacting with or binding to endogenous proteins.  To confirm this 
possibility, in vivo testing with radiolabeled GRFT is suggested to identify if GRFT 
is localizing to or redistributing from, a particular compartment.  Additionally, 
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cellular protein binding experiments may be useful to identify membrane bound 
protein binding partners which may be responsible for GRFT’s long serum 
persistence. 
Subcutaneously dosed GRFT reaches peak serum concentrations at 
approximately 4 hours post administration, with elimination patterns mirroring 
intravenous dosage thereafter.   The initial distribution phase immediately 
following subcutaneously dosage appeared to be fairly comparable regardless of 
amount of GRFT dosed.  However, subcutaneous doses at higher drug 
concentration increased GRFT’s peak concentration, total drug exposure and 
bioavailability, as reflected in the area under the curve over the study period.  It is 
thought that the approximately 4 fold difference in total drug exposure observed 
between 10 mg/kg and 20 mg/kg subcutaneous doses of GRFT could be 
attributable to a gradual release or absorption of more GRFT from the site of 
subcutaneous administration over the time course of treatment while competing 
distributive, elimination, and degradative processes are occurring as it enters the 
circulatory system from the capillary bed.  Interestingly, it appears that the 
concentration of GRFT dosed, and not necessarily the volume of the 
subcutaneous bolus affected total drug exposure over the study period.  A large 
volume, lower concentration of GRFT tested did not have the sustained higher 
serum concentrations (data not shown).     
These pharmacokinetic results would seem to indicate that in a post-
exposure prophylactic setting, subcutaneous administration of GRFT may be a 
viable method of administration.  In the cases of Ebola virus and SARS-CoV, the 
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viral latency period can range from 2 days or longer. In the context of HIV-1 
exposure clinical settings, post-exposure prophylaxis initiated within 24-48 hours 
of exposure has shown a protective effect [120].  Additionally, there are now 
anecdotal evidence that even following seroconversion, immediate treatment with 
anti-viral regimens can confer clinical benefits [196-198], and in the case of an 
infant treated after birth, functional cure [199, 200].   Accordingly GRFT’s 
observed pharmacokinetic profile, peak serum concentrations achieved 4 hours 
post dosing,  and persistence up to 96 hours post single treatment would suggest 
the viability of daily subcutaneous self-dosage regimen to maintain potentially 
therapeutic effect. 
GRFT’s pharmacokinetic parameters will also be important in future 
studies.  Given that subcutaneous dosing may be a viable regimen to maintain 
potentially therapeutic drug concentrations, the pharmacokinetic parameters of 
GRFT may be useful in study design parameters such as: steady state drug 
concentrations, loading doses, maintenance doses, and dosing intervals.  
GRFT’s EC50 for HIV is approximately 40 pM [32].  From the clearance 
parameters (0.06 L/hr) determined for 10mg/kg subcutaneous dosing, a 72 hour 
dosing regimen of 2.5 mg GRFT would achieve a stead state concentration of 47 
nM, over 1000 times higher than GRFT’s EC50 for HIV-1. However, GRFT’sHCV 
EC50 has been described as 14 nM [31], whereas its SARS-CoV EC50 is 
approximately 48 nM [23].  Accordingly, as GRFT is further studied in in vivo 
animal models for varying viral diseases, it may be necessary to design dosing 
intervals and concentrations necessary to maintain serum drug concentrations at 
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potentially therapeutic steady state levels for that disease, while avoiding 
concentrations that may induce toxicities.  For example, with a calculated 14 hour 
elimination-phase half-life seen in a 10 mg/kg subcutaneous dose and a 43% 
bioavailability, a 72-hour dosing regimen would be necessary to minimize 
bioaccumulation of GRFT.  This data can also be utilized to design a more 
frequent dosing regimen to minimize peak and trough concentrations of the drug 
while maintaining a steady state serum concentration above concentrations 
necessary for potentially therapeutic effect.  For instance, to maintain a steady 
state concentration of 47 nM, 35 µg/hr or 840 µg/day would need to be 
administered.  Alternatively, using these data, a loading dose followed by regular 
maintenance dosing may be employed to achieve a desired steady state 
concentrations above the EC50 for particular disease study model.  
Interestingly, it also appears that the concentration of subcutaneously 
dosed GRFT can affect its bioavailability.  At 10mg/kg dosing, GRFT displayed a 
43% bioavailability when subcutaneously dosed. Whereas at 20mg/kg dosing, 
GRFT displayed a 90% bioavailablity (calculated as 
AUC(subcutaneous)/AUC(intravenous) for each respective dose concentration).  
The cause of this discrepancy is currently unclear and will require further study.  
However, it highlights the impact that selection of dose concentration/kg may 
have upon study design. 
In contrast to subcutaneous and intravenous routes, orally administered 
GRFT does not appear to be systemically absorbed.  Other lectins, such as 
wheat germ agglutinin, which bind to N-acetyl-D-glucosamine and sialic acid 
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structures, have been used to increase systemic absorption of some other drugs 
[201, 202].  However, given GRFT’s unique affinity for oligomannose glycans, it 
was uncertain whether GRFT would have a similar utility. At no time point 
examined was GRFT found in the serum of orally-treated animals.  While this 
difference in absorption and elimination profile likely makes GRFT unsuitable as 
an orally dosed systemic therapeutic at this time, advances in drug delivery 
systems for oral dosing of biologics may eventually enable an oral dosing method 
for GRFT. However, GRFT’s current oral dosing profile raises the potential of 
GRFT to be an orally-dosed, rectal microbicide for prevention of transmission of 
HIV-1 and other sexually transmitted pathogens that GRFT is active against 
(such as HSV-2).  Non-absorption of GRFT via oral administration allowed for a 
fraction of the drug to pass through the digestive tract, ultimately being expelled 
in fecal waste (Figure 3.4).  While this fraction is small, approximately 1% of the 
initial dosage, methods to shield GRFT from further effects of stomach acids and 
proteases could possibly be employed to make this fraction higher.  Additionally, 
as food was not controlled prior to oral administration of GRFT, food 
consumption could potentially impact GRFT’s intestinal transit and successful 
proteolytic survival.  Nonetheless, as seen in both the single oral dose mass 
balance as well as the chronic oral dosing, the concentration of GRFT in 
prepared fecal extracts exceed GRFT’s EC50 versus HIV-1 over the first 24 hours 
post treatment.  Interestingly however, GRFT’s neutralization activity in fecal 
extract did not correlate well with GRFT’s previously described EC50 of 40 pM, 
though neutralization activity did correlate well with GRFT concentration.  It is 
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believed that this discrepancy may be attributable to the background 
neutralization activity seen in fecal extracts from PBS treated animals. 
Daily prophylactic treatment for HIV-1 is well established.  For example, Truvada 
is currently being prescribed to high risk populations, namely MSM to prevent 
HIV infection [106, 203].  Additionally, anti-retrovirals are employed following 
occupational and non-occupational exposure to prevent HIV infection [117-120, 
204].  Thus, the observed fractional survival of active GRFT raises the potential 
that GRFT could be utilized as a daily dosed treatment to “seed” the bowels and 
rectal mucosa, where it could potentially block HIV infection through its 
interaction with high mannose glycans on free virions.   
Interestingly, the timing of passage of GRFT following oral dosage also 
appears to be consistent with typical intestinal transit time of 20-30 hours.  As 
seen in Figure 3.2, some animals chronically treated GRFT began to excrete 
GRFT in their fecal matter within 8 hours of initial treatment regardless of dosage 
size.  At 24 hours after treatment, more than half of the animals from each 
treatment group were still excreting GRFT in their feces.  With an intestinal transit 
time of 8-24 hours, it would appear that the majority of GRFT administered is 
passed between 8-20 hours of dosage in rats.  However, it is currently unknown 
what effect the co-administration of food would have upon GRFT’s transit time as 
food was only restricted 20 minutes before administration.  It is very possible that 




While enveloped viruses such as SARS-CoV, HIV-1, HSV-2 and HCV 
continue to spread worldwide, it is imperative that all avenues for prevention be 
evaluated to assess their overall population level effect.  Our findings indicate 
that GRFT’s pharmacokinetic profile supports multiple potential uses as well as 
enables the design of different dosing regimens.  As a systemic post-exposure 
therapeutic or treatment, subcutaneous self-dosing would be both a viable and 
effective means to achieve potentially therapeutic serum concentrations of 
GRFT.   In the context of post-exposure prophylaxis to emerging viral threats, an 
initial intravenous bolus treatment may be useful to achieve very rapid peak 
serum levels of GRFT (Figure 3.1.) Further, given the apparent non-absorption of 
GRFT following oral administration, as well as the continued anti-viral activity of 
GRFT found in fecal materials, it is possible that GRFT could be utilized as an 
orally dosed rectal microbicide in a pre-exposure prophylactic setting.  While 
admittedly, it is only a small fraction of GRFT dosage which survives intestinal 
transit, we have demonstrated that levels above its anti-HIV EC50 are achievable.  
Nonetheless, methods may be needed to shield GRFT from excessive 










Figure 3.1. Pharmacokinetic profile of GRFT in Serum.  Mean GRFT 
concentrations present after single Intravenous (IV) and Subcutaneous (SQ) 
dose (n=3-4 per group) (A).  Serum Concentrations from animals dosed with 10 
mg/kg GRFT both 72 and 96 hours after administration (B).  Bars indicate mean 


























hr -- -- 1.3 ± 0.3 1.6 ± 0.4 
 
DISTRIBUTION 
HALF LIFE  
(4-8 HR) 
 
hr 1.7 ± 0.3 2.1 ± 0.7 2.1 ± 0.9 2.8 ± 1.2 
 
ELIMINATION 
HALF LIFE  
(24-48 HR) 
 
















µg/ml 80 ± 30 180 ± 30 6.6 ± 0.6 20 ± 2 
 
 
Table 3.1.  Pharmacokinetic parameters of GRFT over 48 hours.  Data represent 
the mean values +/- standard deviation for initial distribution (intravenous),  
absorption (subcutaneous), distribution, and elimination half-lives, area under the 
curve (AUC), volume of distribution (VD), clearance, and maximum serum 




Figure 3.2.  GRFT Concentrations in Fecal Extracts following Chronic Oral 
dosing.  Mean GRFT concentrations from fecal extracts prepared from fresh fecal 
pellets obtained 8 hours (A) and 24 hours (B) after oral dosage with either PBS, 5 
mg GRFT, or 10 mg GRFT.  Bars indicate mean ± standard deviation of 5 
biological replicates. Mean GRFT concentrations of fecal extracts prepared from 
desiccated pellets randomly drawn from cages (two animals per cage) on select 







Figure 3.3. Antiviral activity of pooled fecal extracts collected on select days 
during the course of chronic oral treatment with GRFT. HIV-1 env- pseudovirus 
neutralization activity (EC50 of GRFT = ~40 pM) was assessed for pooled rat fecal 
extracts from animals dosed with either PBS, 5 mg or 10mg GRFT and 
expressed as ID
50 
(dilution factor required to reduce luminescence to 50% of 
PBS treated controls) (A).  The mean GRFT concentrations were determined and 
compared to interpolated ID
50





Figure 3.4.  Total GRFT recovery following single administration.  Based upon 
likely route of excretion, urine or fecal samples were obtained for animals 
receiving 10 mg/kg GRFT after Intravenous (IV), Subcutaneous (SQ), and oral 
administration. GRFT concentrations in urine and fecal extracts were determined 
and mean GRFT recovered was calculated. Bars indicate mean ± standard 
























































































SUB-CHRONIC SUBCUTANEOUS TREATMENT WITH THE ANTIVIRAL 
LECTIN GRIFFITHSIN IN RATS TO DETERMINE GRIFFITHSIN’S SYSTEMIC 
TOLERABILITY AND EXAMINE GRIFFITHSIN’S EFFECTS UPON ORGANS, 
BLOOD CELL COUNTS, SERUM CHEMISTRIES, AND CYTOKINE 
PRODUCTION 
INTRODUCTION 
The oligomannose glycan structures displayed on the surface of many 
human and animal pathogenic viruses are potential targets for antiviral 
therapeutics.  CBAsact by targeting and binding to viral oligomannose glycans 
and include both lectin and non-peptidic drugs [14, 205]. CBA relevance in viral 
therapy stems from the fact that, among enveloped viruses, glycans shields can 
be used for cellular entry, immune evasion, and in some cases, innate immune 
response suppression[13, 17, 19, 51, 60].  In vitro antiviral activity of CBAs 
against a broad array of enveloped viruses has been observed and verified by 
others [28, 29, 189]. However, most carbohydrate binding agents  that display 
broad spectrum, strongly inhibitory antiviral activity are lectins that present 
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several theoretical safety concerns for development as biologic therapies[14, 22, 
24, 149].  Chief amongst the safety concerns are toxicities associated with off-
target activity, and immunotoxicities including hypersensitivity and production of 
anti-drug antibodies (ADA) that might neutralize the lectin antiviral activity and 
lead to undesirable side effects over long-term therapy.  
One of the most promising antiviral lectins is the red alga Griffithsia-
derived homodimeric lectin Griffithsin.  GRFT (12.77 kDa) is a lectin that binds 
terminal mannose residues on (N)-linked Man5-9GlcNAc2 structures on viral 
envelopes [32, 163, 165].  These oligomannose glycans comprise the vast 
majority of N-linked glycans in the HIV-1 glycan shield [13, 16]. Consequently, 
GRFT has exceptional activity—in the mid picomolar range—against the heavily 
glycosylated lentiviruses HIV-1 and HIV-2[32, 33], and nanomolar inhibitory 
activity against other viruses of public health importance, such as HCV [30, 31], 
JEV [173]  as well as SARS-CoV in addition to other CoV pathogens [23]. Data 
published by our group and others show that GRFT does not induce 
inflammatory cytokines on treatment of cultured human cells and primary 
lymphocytes; does not agglutinate human red blood cells; shows an excellent 
safety profile in highly sensitive preclinical safety models designed to predict 
toxicity at vaginal epithelia; and shows minimal toxicity after short-term oral, 
subcutaneous and intravenous exposure.   Much like the in vivo studies into the 
efficacy of CBAs as antiviral treatments to inhibit influenza and Ebola viruses [28, 
29], in vivo and ex vivo studies using GRFT in multiple murine virus challenge 
models have also shown promise.  For example, intranasally administered GRFT 
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prevents disease in mice challenged with SARS-CoV [172].  Intraperitoneal (IP) 
treatment with GRFT has prevented JEV [173].   Furthermore, GRFT showed 
efficacy against HCV in a mouse-human chimeric liver model when administered 
subcutaneously [30, 170]. 
Our previous studies have shown that an acute subcutaneous treatment of 
GRFT in guinea pigs and mice for a period of ten (10) days was tolerable with 
minimal toxicity reported [34].  We also showed that subcutaneous administration 
of GRFT at 10 mg/kg remains at potentially therapeutic concentrations up to 48 
hours after administration, with therapeutically-relevant concentrations persisting 
for over a week after a single 50 mg/kg administration in mice [34].  However, as 
a xenogeneic protein, GRFT has the potential to elicit an immune response, up to 
and including anaphylaxis.  Accordingly, longer term administration studies are 
necessary to assess GRFT’s potential as a systemic therapeutic.  Furthermore, 
the impact that ADA may have on GRFT’s pharmacological activity, 
pharmacokinetics, and in vivo toxicity profile is unknown.  
Here we report that minimal toxicity is induced by subcutaneous doses of 
GRFT in rats after approximately 8 weeks of treatment, though development of 
immune responses that may cause IgG ADA may require more prolonged and 
periodic monitoring.  The drug remained systemically distributed, and 
accumulated at physiologically relevant levels after subcutaneous delivery for all 
time points tested.  Inflammatory cytokine analysis at treatment cessation did not 
reveal widespread alterations in inflammatory cytokine levels, though some 
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significant changes were observed in macrophage inflammatory proteins and 
leptin levels.  Importantly we demonstrated that serum from GRFT treated 
animals retained anti-viral activity against HIV-1 envelope pseudoviruses in a cell 
line-based neutralization assay despite a modest ADA response to the GRFT. 
Overall, these findings support further investigation into GRFT’s potential as a 














MATERIALS AND METHODS 
Lectin reagents 
Recombinant GRFT was produced as described previously, purified to 
>99% purity, and formulated in phosphate buffered saline (PBS), pH 7.4 [169]. 
Animal housing and care 
225-250g Sprague Dawley Rats (Rattus Norvegicus, Charles River 
Laboratories), housed in a temperature- and humidity-controlled room with an 
alternating light/dark cycle of 12h, were provided a standard diet and water ad 
libitum. All experimental procedures utilized were approved by the University of 
Louisville’s Institutional Animal Care and Use Committee. 
Rat IgG Generation  
To generate IgG antibodies for passive immunization, 9 Sprague Dawley 
rats (250g+) were injected subcutaneously with 500 µl Sigma Adjuvant 
(monophosphoryl lipid A, synthetic trehalose dicorynomycolate in 2% squalene-
Tween® 80-water) and GRFT formulated at 1mg/ml per manufacturer’s 
recommended protocol.  Booster immunizations were performed according to 
manufacturer protocol every 3 weeks for 12 weeks. Two weeks after final 
immunization animals were sacrificed by CO2 asphyxiation and serum was 
collected via cardiac puncture. Ig from these samples was purified by NAB spin 
column (Sigma) according to the manufacturer’s protocol.   For nonspecific 
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controls, IgG from commercial Sprague Dawley rat serum (InnovoResearch) was 
purified by NAB spin column (Sigma).  Ig was then dialyzed (Thermo 3500 
mwco) against PBS to remove elution buffer and sterile filtered prior to 
subcutaneous administration. 
Rat treatment and sample collection 
Age-matched, 225g Sprague Dawley rats were allowed to a week to 
acclimate before treatment according to the treatment regimen diagram shown in 
Figure 4.1.  After acclimation, two groups were pre-immunized with either 0.5 ml 
of Sigma Adjuvant and GRFT at 1mg/ml (n=7) or 0.5 ml Sigma Adjuvant and PBS 
(n=6) before commencing treatment.  Pre-immunized animals were boosted 
twice at three week intervals. Animals not undergoing pre-immunization were left 
fallow during the pre-immunization phase.  Treatment groups consisted of the 
following: pre-immunized with Adjuvant and PBS (n=6), pre-immunized with 
GRFT and Adjuvant (n=7), GRFT treated (n=7), PBS treated (n=6), GRFT treated 
and passively immunized with anti-GRFT Ig (n=7), PBS treated and passively 
immunized with nonspecific Ig (n=6).  Animals were treated subcutaneously with 
either PBS or 10mg/kg GRFT every three days.  Passively-immunized animals 
also received 1.4 mg of appropriate Ig formulated in 1 ml of PBS every 14 days.   
Serum was drawn via lateral tail vein on the following days: Day 10, 24, 
38, and 52. Animals were sacrificed on day 55 via CO2 asphyxiation followed by 
cardiac puncture exsanguination.  Blood, hearts, lungs, kidneys, liver, spleen, 
colon, and vaginas were collected at sacrifice for analysis. 
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GRFT capture immunoassay using the HA glycoprotein. 
To detect active concentrations of GRFT present in serum we used an 
Influenza HA binding ELISA.  Briefly, Maxisorp plates (Nunc) were coated with 10 
µg purified HA (Kentucky Bioprocessing) and incubated overnight at 4oC.  Plates 
were blocked with ~3% (w/v) Bovine Serum Albumin (BSA) in PBS-T.  Serum 
samples were diluted 1:10 in blocking buffer. Serial dilutions of purified GRFT 
were run in parallel for generation of a standard curve. Serum and GRFT 
dilutions and were incubated at RT for 1 hour.  HA-bound GRFT was detected by 
rabbit anti-GRFT antiserum (1:25,000) followed by HRP-conjugated goat anti-
rabbit IgG (1:10,000).  Plates were developed with SureBlue TMB Microwell 
Peroxidase Substrate, with reactions stopped with 1N H2SO4 after 10 minutes of 
development.  Absorbance readings at 450 nm and 570 nm wavelengths were 
measured using a BioTek Synergy HT plate reader.  Concentrations were 
determined by Nanoanalyze software. 
Evaluation of Anti-HIV Activity.   
HIV-1 neutralization activity of heat-inactivated serum samples obtained 
on day 52 and 55 was measured using pseudovirus neutralization assays as 
previously described [174]. Briefly, DU156 env-pseudotyped virus particles 
generated by transfection of 293T cells were titrated in TZM-bl cells both in the 
presence and absence of serum sample dilutions.  Antiviral activity of the serum 
samples was calculated as a function of luciferase activity. ID50 values were 
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defined as the sample dilution required to reduce well luminescence by 50% in 
comparison to wells with no sample added.  
Hematology parameters and Serum Chemistry.   
A complete blood count (CBC) was run for terminal bleed samples using a 
Hemavet® 950 (Drew Scientific) standardized for rat blood. Parameters 
quantified in potassium-EDTA anti-coagulated whole blood included: red blood 
cells (RBC; 104/µl), total and differential leukocyte count (neutrophils, 
lymphocytes, monocytes, eosinophils, and basophils as 103/µl or %), hemoglobin 
concentration (HGB; g/dl), hematocrit (HCT; %), mean corpuscular volume (MCV; 
fl), mean cell hemoglobin (MCH; pg), mean cell hemoglobin concentration 
(MCHC; g/dl), red cell distribution width (RDW; %), platelets (PLT; 104/µl), and 
mean platelet volume (MPV; fl). 
Serum chemistry panels were also run for terminal bleed samples using a 
VetTest® Chemistry Analyzer (IDEXX Laboratories). Parameters quantified from 
serum included: serum albumin (Alb), alkaline phosphatase (ALKP), amylase 
(Amy), alanine aminotransferase (ALT), blood urea nitrogen (BUN), calcium (Ca), 
cholesterol (Chol), creatinine (Creat), globulin (Glob), glucose (Glu), phosphorus 
(Phos), total bilirubin (TBil), and total protein (TP).  
Rat Antibody titration 
To quantitate degree of immune response to GRFT, antibody titers were 
determined for terminal bleed samples (day 55) using a sandwich ELISA.  Briefly, 
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Maxisorp plates (Nunc) were coated with 5 ug purified HA (Kentucky 
Bioprocessing) and incubated overnight at 4C.  Plates were blocked with ~3% 
(w/v) Bovine Serum Albumin (BSA) in PBS-T.  10ug/ml GRFT (to excess) was 
diluted in blocking buffer and incubated at RT for 1 hour.  Serial dilutions of 
sample sera diluted in PBS-T containing 2M urea were incubated in wells for 2 
hours. GRFT-bound rat Ig was detected by HRP-conjugated Donkey anti-rat 
polyclonal antibody (1:25,000).  Plates were developed with SureBlue TMB 
Microwell Peroxidase Substrate, with reactions stopped with 1N H2SO4 after 10 
minutes of development.  Absorbance readings at 450 nm and 570 nm 
wavelengths were measured using a BioTek Synergy HT plate reader.  Final 
absorbance 2 times background was considered a positive signal for a particular 
dilution.   
Cytokine Quantitation 
To measure any inflammatory effects of chronic exposure, cytokine levels 
in samples drawn on day 52 were determined by Milliplex Map Kit (Millipore) 
using manufacturer’s standard protocol.  The following cytokine levels were 
quantified: granulocyte colony-stimulating factor (G-CSF), Eotaxin, Granulocyte 
macrophage colony-stimulating factor (GM-SCF), Interleukin 1 alpha (IL-1a), 
Leptin, Macrophage Inflammatory Protein 1 alpha (MIP 1-a), Interleukin 4 (IL4), 
Interleukin 1 beta (IL-1B), Interleukin two (IL-2), EGF, Interleukin 13 (IL-13), 
Interleukin 10 (IL-10), Interluekin 12 (IL-12p70), Interferon gamma (INFy), 
Interleukin 5 (IL-5), Interleukin 17 alpha (IL-17A),  Interleukin 18 (IL-18), 
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monocyte chemoattractant protein 1 (MCP-1), interferon gamma induced protein 
10 (IP-10), growth-related oncogene (GRO/KC), vascular endothelial growth 
factor (VEGF), Fractalkine, lipopolysaccharide induced CXC  chemokine (LIX), 
macrophage inflammatory protein 2 (MIP-2), tumor necrosis factor alpha (TNFa), 
and Rantes. 
Statistical Analysis.  
Statistical analysis was conducted using Graph Pad Prism 5.  Two-way 
ANOVA was utilized.  A p-value < 0.05 was deemed significant.  Bonferonni post-
tests were conducted to determine whether any differences were attributable to 












GRFT serum concentrations.   
Serum samples collected from all rats treated with 10mg/kg GRFT showed 
nanomolar concentrations of GRFT at every time point tested (Figure 4.2A).  
These levels predictably varied by time since last dosage, which ranged from 24 
to 72 hours after administration. In Day 52 sera (24 hours after final 
administration), all groups treated with GRFT displayed active mean GRFT 
concentrations of approximately 10 nM. Notably, these concentrations of GRFT 
persisted at mean levels of approximately 4 nM, regardless of GRFT treatment 
subgroup, at 96 hours after dosing.  Serum concentrations from GRFT treated 
animals were also compared to serum concentrations from prior single 
subcutaneous administration studies described in Chapter 3 (Figure 4.2B).  Mean 
GRFT concentrations in animals chronically treated with GRFT were higher at all 
time points versus serum concentrations from animals receiving a single dose. 
Anti-GRFT and Anti-HIV Activity of serum.   
Serum Samples displayed varying levels of Anti-GRFT activity based upon 
treatment group (Figure 4.3A).  GRFT treated animals (without pre-immunization) 
showed GRFT titers slightly elevated over background.   Animals receiving 
passive Ig immunization and pre-immunization with GRFT and adjuvant had the 
highest mean activity titrations at 1:767 and 1:1542 respectively.  There was clear 
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variability in the GRFT antibody titers in both the pre-immunized and passively 
immunized groups.  
Serum samples collected from rats treated with 10 mg/kg GRFT 
neutralized HIV-1 pseudoviruses (Clade C primary sexually transmitted isolate 
Du156) with an overall mean ID50 of approximately 20500 on experimental day 
52 (Figure 4.3B).  The antiviral activity measured in rat sera was not statistically 
different between animals that were immunologically naïve at the study outset 
(GRFT group) versus the preimmune group and the passively immunized group. 
After a 96 hour recovery period, group mean ID50 values decreased to 
approximately 4300 on day 55.   PBS treated rat sera displayed a mean ID50s of 
264 and 112 on days 52 and 55, respectively.  Both pre-immunized and passively 
immunized groups also receiving GRFT treatment displayed strong neutralization 
activity on Day 52 as well, with mean ID50 values of 19800 and 17000 
respectively.  These group mean ID50s also decreased 96 hours after treatment, 
similarly to animals treated only with GRFT.  Rat neutralization titers did not 
correlate well with GRFT’s published anti-HIV-1 EC50 of 40 pM, likely as a 
product of background neutralization activity observed in rat serum. 
GRFT is well tolerated after chronic subcutaneous administration 
We studied the toxicity of GRFT in rats using several parameters including 
mortality, behavior, animal body and organ weight changes, tissue pathology, and 
changes in blood properties. 
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All animals survived treatment with no behavioral changes observed.  
Body weight, as a surrogate marker for overall fitness following GRFT treatment, 
was evaluated.  Animals were weighed at day 1 and day 55. Using a 2-way 
ANOVA, we found no significant changes in starting weight or weight gain among 
treatment groups (p=0.4177 and p=0.9170 respectively, Figure 4.4). 
Liver, kidney, and spleen weights were measured at sacrifice and 
normalized to total body weights.  No significant changes of the normalized 
weights of livers were observed (p= 0.1487, Figure 4.4C) However, animals 
passively immunized with GRFT IgG and treated with GRFT displayed 
significantly lower kidney/body weight ratios in comparison to PBS treated 
controls (p=0.0328, Figure 4.4D). Additionally, we observed a trend toward larger 
spleen weights in all animals treated with GRFT, regardless of whether they were 
pre-immunized (p=0.0561, Figure 4.4E).  
Tissue sections were stained with hematoxylin and eosin and evaluated in 
a blinded fashion by a veterinary pathologist (MaryProctor).  The pathologist 
noted differences among individual animals that were attributable to sample 
preparation and sectioning.  However, no treatment-related pathologies were 
observed for any treatment group.  
CBC results displayed no significant changes among groups though Red 
Blood Cell Width and Platelet values approached significance with p-values of 
0.0977 and 0.0796 respectively (Table 4.1).  Serum chemistries displayed some 
statistically significant differences among treatment groups (Table 4.2).  Among 
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these were albumin, amylase, phosphorus, blood urea nitrogen, and globulin.  
Bonferroni post-test identified differences among treatment groups.  Phosphorus 
levels were significantly higher in vehicle-only (PBS) than in all GRFT treated 
groups (p=0.0083).  Amylase and globulin levels were significantly higher in 
Passively Immunized/GRFT treated animals though amylase levels were within 
the normal range for rats (p=0.0468 and p=0.002 respectively).  Finally, albumin 
levels were significantly lower in pre-immunized/GRFT treated animals than in 
PBS treated controls, though within the normal range for rats (p=0.0071). 
Cytokine responses 
Cytokine panels with a minimum of 3 positive signals per group were 
analyzed.  Analysis of PBS, GRFT, Pre-Imm/GRFT, and Pass-Imm/GRFT 
revealed only 4 significant differences among the cytokines examined:  Leptin, 
MIP-1a, Ip-10, and MIP-2 (Table 3).  In the case of leptin, all groups treated with 
GRFT had significantly lower leptin levels than PBS treated controls (p=<0.0001).  
Further, IP-10 levels were lower in the group receiving GRFT-only treatment 
(p=0.0312).  MIP-1a elevation was seen in the pre-immunized/GRFT treated 
group (p=0.018).  However, posttest analysis did not reveal significance versus 
PBS-treated controls, but rather significance versus GRFT-only treated animals.  
Finally, MIP-2 displayed a significant difference among treatment groups 






In this study, we demonstrate that intermediate term sub-chronic GRFT 
administration is tolerated in rats, despite high levels of experimentally induced 
ADA.  Levels of ADA varied among groups and also varied widely within groups.  
High anti-GRFT antibody titers were not observed in any animal even when pre-
immunized with adjuvant.  Regardless of ADA levels, GRFT persisted in serum at 
concentrations above the EC50 described for multiple enveloped viruses [23, 31, 
32, 178].  Further these levels were observed in all GRFT treated animals, at all 
time points tested, and up to 96 hours after administration. Although predictably 
decreasing after final administration, functionally active GRFT concentrations--as 
determined by HA binding ELISA and HIV-env pseudovirus neutralization assay--
remain in circulation for many days after treatment cessation.  These findings 
support the continued study of GRFT as a viral therapeutic.   
As noted in prior studies, a favorable safety profile for a drug must be 
demonstrated to advocate for its further development [34, 35]. We observed 
previously that GRFT was capable of persisting in the system for many days after 
administration at potentially therapeutic levels when subcutaneously or 
intravenously dosed ([34] and manuscript in preparation).  Thus greater time 
between administrations was selected to mimic a more favorable dosing regimen 
that would be more acceptable for those relying upon subcutaneous self-
administration while not allowing GRFT to completely clear systemic circulation. 
Based upon prior work, which described GRFT’s clearance in rats following 
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subcutaneous administration at 10mg/kg at 0.058 L/hr, a dosing regimen of 2.5 
mg every 72 hours was calculated to generate steady state concentrations of 
GRFT of 47 nM, over 1000 times GRFT’s anti HIV-1 EC50 of 40 pM.  Further, 
this extended dosing regimen was sufficient to keep GRFT in the system at 
concentrations well above its EC50 for HIV at 96 hours after final dose, thus 
suggesting longer potential periods between administrations in humans may also 
be possible, if not ideal.  Injection administration of antiviral therapies is not 
unheard of, and research is currently being conducted into long acting anti-viral 
medications for HIV prevention and treatment [206-208].  Accordingly, efforts to 
prolong GRFT’s serum persistence may be necessary to further enhance an 
already acceptable administration profile. 
In these current in vivo studies in rats, GRFT was not observed to alter 
experimental animal behavior, nor did any animal die as a result of treatment. 
Potential organ toxicity was also assessed by visual inspection during necropsy, 
weight measurements and histopathology. No differences in organ appearances 
were observed during necropsy.  While kidney weight percentages of total body 
weight in passively immunized/GRFT treated animals displayed a statistically 
significant lower percentage in comparison with PBS-treated controls and pre-
immunized/GRFT treated animals trending toward lower percentages as well, 
histopathological examination of the organs did not show any treatment-related 
pathologies. Given the animals in this study were still growing, these lower 
percentages may be a result of either impaired kidney growth or potential 
nephrotoxicity.  A prior study (manuscript currently in preparation) showed a 
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significant excretion of active GRFT into urine after both intravenous and 
subcutaneous systemic administration.  Accordingly, given that the observed 
changes in kidney weights were seen in animals in which had significantly higher 
globulin levels, it is possible that GRFT-antibody complexes or some component 
on an immune response have an impact upon the renal function.  Further 
supporting this possibility was the observed trend toward lower kidney weight 
and higher globulin levels also observed in pre-immunized/GRFT treated 
animals.  Accordingly, further study will be necessary to determine how an 
antibody response impacts kidney function given that no histopathological 
abnormalities were observed by the veterinary pathologist (M.P.). 
When a complete blood count was performed and serum chemistries 
analyzed, we observed that no CBC parameters were significantly changed as a 
result of GRFT treatment.  However, serum chemistries did show some variation. 
Post hoc analysis revealed that amylase and globulin levels were significantly 
higher in passively-immunized/GRFT treated animals versus PBS treated 
controls. While amylase levels were still within the normal range for rats, elevated 
globulin levels could reasonably be expected as an outcome of Ig administration, 
and thus could be a confounding effect derived from the experimental treatment.  
Significant differences in albumin and BUN in pre-immunized animals 
versus PBS treated controls were observed.  Interestingly, the difference in BUN 
combined with the trend toward a lower kidney to bodyweight ratio may suggest 
a degree of kidney impairment associated with an immune response to GRFT 
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which impairs kidney excretion of urea, as elevated BUN levels can be indicative 
of kidney malfunction [209, 210].  Finally, a difference in phosphate levels was 
observed in PBS treated animals in comparison with all GRFT treated groups.  
However, closer analysis revealed that the PBS group average may have been 
skewed by two high values and all values for phosphate were within the 
physiological normal range for rats. 
While prior studies have demonstrated that GRFT is not mitogenic, is not 
cytotoxic to cells, and does not induce cell mediators of inflammation [35], a 
major concern with an immune response to GRFT is that, as a xenogenic protein, 
anaphylaxis is possible [180].  Although GRFT is a relatively weak immunogen, 
we were able to raise a modest IgG antibody response in animals pre-immunized 
with GRFT in the presence of adjuvant. Fortunately, it appears based upon both 
ELISA and pseudovirus neutralization assay that immune sera are binding, but 
non-neutralizing.   
Immunogenicity of biologic drugs such as GRFT is a known issue and in 
this study we demonstrate that while tolerable, some physiological changes may 
be induced by an IgG based immune reaction to GRFT. Despite differing IgG 
models of an immune response, it appears that GRFT administration does not 
significantly impact the majority of cytokines examined.  This corroborates prior 
studies suggesting that GRFT does not induce cell mediators of inflammation 
[35].  Nonetheless, there were some notable exceptions. The most significant 
difference observed was in leptin levels.  Leptin is a hormone made by body fat 
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to regulate food intake and body weight.  However, it has also been implicated in 
T-cell regulation as well as inflammation, wherein leptin is considered pro-
inflammatory and proangiogenic [211].  These findings of decreased leptin levels 
in all GRFT treated groups may indicate some anti-inflammatory effect of GRFT 
treatment.  However, further studies into GRFT’s interactions with leptin are 
needed to determine the exact mechanism by which leptin levels are lowered, 
though interestingly, a lower body weight gain was observed in guinea pigs 
treated with GRFT in a previous study [34].  This same conclusion may be drawn 
from IP-10 levels.  IP-10 (interferon inducible protein-10) levels were significantly 
lower in animals receiving GRFT treatment in absence of pre-immunization or 
simulated immune response.  Thus, in animals in which no immune response 
was generated or simulated, IP-10 levels were seen to decrease, further 
supporting the possibility that GRFT may have some discrete anti-inflammatory 
activity.  However, once an immune response was initiated, it seems this effect 
may disappear.  MIP-1a and MIP-2 were elevated in animals pre-immunized with 
GRFT and adjuvant.  In the case of MIP-1a, the elevation was significant in pre-
immunized/GRFT treated animals versus PBS treated controls.  In the case of 
MIP-2, ANOVA post hoc analysis did not reveal the source of the variation.  
However, both GRFT and GRFT/passively immunized animals displayed 
decreased levels of MIP-2 verses PBS controls, while the pre-immunized GRFT 
treated group was elevated versus PBS controls.  While further study into the 
exact effect of GRFT on these cytokines will be necessary, these results seem to 
suggest that GRFT may function to slightly decrease inflammation. These results 
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also raise the possibility that GRFT may have an immunosuppressive effect.  
Further immune suppression would likely be undesirable in HIV disease and may 
present a barrier to usage in those with existing infections.  Additionally, the 
specter of immunosuppression may require additional testing, such as viral, 
bacterial, and tumor infection challenges as well as a full complement of in vitro 
cell activation assays to ensure that GRFT does not prevent humoral or adaptive 
immune response to other pathogens. 
Resistance to CBAs occurring through a loss of specific N-linked 
glycosylation sites has been observed when those viruses are placed under drug 
pressure with CBAs [25, 185-188]. In HIV-1, CBA resistance has been correlated 
with reduced viral fitness leading to a potentially enhanced susceptibility to 
endogenous antibody neutralization [14, 186, 188]. Thus it has been 
hypothesized by Balzarini and others that CBA therapy may induce resistance to 
the CBA while enhancing susceptibility to immune system neutralization, 
particularly in the case of HIV-1[14].  GRFT’s continued antiviral activity even in 
presence of an immune response, as well its ~8 week tolerability profile, would 
seem to indicate that GRFT is a candidate drug to test that hypothesis, as it 
could be used for longer intermittent periods in attempts to guide viral resistance 
evolution.     
These results demonstrate that despite both pre-immunization and 
passive immunization, no animal mortality was observed in any treated animal. 
Furthermore, unlike our prior studies in guinea pigs and mice, our current data 
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does not show significant treatment-associated increases in spleen and liver 
mass-to-bodyweight ratios, though spleen differences approached significance, 
probably associated with an immune response to GRFT.  However, it does 
appear that an immune response may result in kidney involvement, the exact 
nature of which is not clear at present.  As such, future efforts to de-immunize 
GRFT may be necessary [161, 162], before it is viable as a long-term chronic 
treatment of viral infection in humans. Nonetheless, we conclude that the 
preliminary toxicity profile of GRFT is acceptable and encourages its further 









Figure 4.1.  Treatment Regimen to evaluate the impact of an immune response 
upon GRFT’s systemic tolerance and activity.  Animals were separated into 
groups of 6-7 animals and dosed every 3 days with either PBS or GRFT during 
course of treatment.  Select groups were pre-immunized prior to treatment 
commencement (3 and 5) or passively immunized with IgG during chronic 





Figure 4.2.  GRFT serum concentrations in rats during and after chronic GRFT 
treatment and comparisons with single dose pharmacokinetic values.  (A) GRFT 
concentrations were determined (12.77 kDA) from rat sera of naïve, pre-
immunized (pre-imm), or passively immunized (passive-imm) animals following 
chronic PBS or 10mg/kg GRFT administration on day 10 (24 hrs after dosage), 
day 24 (72 hours after dosage), day 38 (48 hours after dosage), day 52 (24 hours 
after dosage), and day 55 (96 hours after dosage).  PBS was administered to 
control animals Error bars indicate standard deviation of 7 biological replicates. 
(B) Mean GRFT concentrations of chronic dosing and a single subcutaneous 
dose (projected using Clearance value of 0.058L/hr) reflect minor GRFT 




Figure 4.3. Titers of anti-GRFT IgG and antiviral activity of sera from rats pre-
immunized against GRFT, passively immunized with GRFT IgG, and controls. 
Anti-GRFT activity of Rat serum at Day 55 was evaluated via titration (A).  HIV-1 
env-pseudovirus neutralization activity was assessed for rat sera 24 hours after 
final administration of GRFT (Day 52) and 96 hours after final administration (Day 
55) (B).  Antiviral activity was expressed as ID50.  Control animals were treated 
with PBS. Anti-HIV-1 EC50 of GRFT = ~40 pM. Bars indicate mean group 
















Figure 4.4. Starting weight, weight gain over treatment, and Organ percentages 
from rats preimmunized against GRFT, passively immunized with GRFT IgG, and 
controls.  Animal bodyweights were measured on experimental day 1 (A) and at 
termination.  Weight gain over treatment was calculated for each animal (B).  
Liver (C), Kidney (D) and Spleen (E) weights were measured relative to body 
weight at sacrifice.  Bars indicate group mean and standard deviation of 6 to 7 
biological replicates.  Significant (p<0.05, One way ANOVA with Bonferroni 


























Leukocyte WBC K/µL 7.86±2.22 8.98±2.80 10.53±3.90 8.75±4.82 0.5978 
 Ne K/µL 2.63±0.60 3.05±1.16 3.66±1.30 2.77±1.50 0.4281 
 Ly K/µL 4.62±1.59 5.35±1.60 6.04±2.45 5.37±3.02 0.7317 
 Mo K/µL 0.37±0.21 0.41±0.24 0.62±0.32 0.38±0.33 0.3267 
 Eo K/µL 0.19±0.10 0.14±0.13 0.16±0.18 0.16±0.10 0.9540 
 Ba K/µL 0.05±0.04 0.03±0.05 0.04±0.04 0.05±0.02 0.9269 
Erythrocyte RBC M/µL 6.63±0.51 6.33±0.79 6.55±0.54 6.07±1.39 0.6663 
 Hb g/dL 14.0±0.6 13.7±0.7 13.4±1.3 12.5±2.3 0.2428 
 HCT % 37.0±1.9 34.2±4.8 35.2±2.8 32.7±8.0 0.4891 
 MCV fL 55.9±2.8 54.0±2.8 53.7±1.1 53.7±1.4 0.2442 
 MCH pg 21.2±1.0 21.9±3.4 20.4±0.9 20.8±1.6 0.5537 
 MCHC g/dL 37.9±1.4 40.8±7.4 38.0±1.6 38.7±4.1 0.6119 
 RDW % 14.0±0.5 13.8±0.6 14.4±0.4 14.4±0.4 0.0977 
Thrombocyte Plt K/µL 859±314 890±325 655±185 542±184 0.0796 
 MPV fL 7.5±0.4 7.6±0.3 7.5±0.4 7.7±0.4 0.7263 
 
Table 4.1.  Hematological profile for rats after chronic treatment with GRFT.  
Data represent the mean values +/- standard deviation for white blood cells 
(WBC), neutrophils (NE), lymphocytes (LY), monocytes (MO), eosinophils (EO), 
basophils (BA) , red blood cells (RBC), hemoglobin (Hb), hematocrit (HCT), 
mean corpuscular volume (MCV), mean cell hemoglobin (MCH), mean cell 
hemoglobin concentration (MCHC), red cell distribution width (RDW), platelets 
(PLT), and mean platelet volume (MPV).  Significance (p<0.05, ANOVA) is 
























ALB g/dL 3.8-4.8 5.1±0.9 5.0±0.3 4.2±0.3* 4.5±0.2 0.0071 
ALKP U/L 16-302 82±13 62±22 97±33 94±30 0.0767 
ALT U/L 20-61 100±29 74±19 79±45 72±22 0.3717 
AMYL U/L 326-2246 1336±155 1577±236 1554±180 1681±190* 0.0468 
CA mg/dL 5.3-11.6 12.2±0.4 12.3±0.7 12.0±0.3 12.1±0.5 0.7027 
CHOL mg/dL 20-92 96±20 116±15 105±12 110±12 0.1292 
CREA mg/dL 0.1-0.6 0.3±0.1 0.4±0.1 0.4±0.0 0.3±0.1 0.1103 
GLU mg/dL 50-135 194±53 153±30 153±29 151±44 0.1898 
PHOS mg/dL 5.8-11.2 10.4±1.8 8.4±0.9* 8.4±0.9* 8.3±0.8* 0.0083 
TBIL mg/dL 0.1-0.7 1.9±1.8 1.0±0.6 0.6±0.2 0.9±0.8 0.1498 
TP g/dL 5.3-6.9 8.7±1.6 8.4±0.4 8.0±0.3 8.4±0.4 0.4511 
BUN mg/dL 9-21 21±4 19±2 23±2 23±3 0.0453 
GLOB g/dL 1.5-2.8 3.4±0.3 3.4±0.3 3.8±0.2 3.9±0.2* 0.002 
 
Table 4.2.  Serum Chemistry panels of animals after chronic treatment with PBS 
or GRFT.  Data represent mean values +/- standard deviation for albumin (alb), 
alkaline phosphatase (ALKP), Alanine Transferase (ALT), amylase (AMYL), 
calcium (Ca), cholesterol (Chol), Creatinine (Crea), glucose (Glu), phosphorus 
(Phos), total bilirubin (Tbil), total protein (TP), blood urea nitrogen (BUN), and 
globulin (Glob).  One-way ANOVA with Bonferroni post-test significance versus 
























G-CSF 11.07±2.88 17.25±10.48 16.82±19.07 19.97±10.16 0.8646 
EOTAXIN 6.12±3.09 8.11±4.32 9.24±4.16 10.06±2.36 0.2805 
IL-1A 160.87±145.05 75.97±66.76 60.29±28.39 94.75±59.74 0.2139 
LEPTIN 29769.12±4573.37 15093.69±8081.77* 17452.83±3928.75* 13823.71±4018.78* <0.0001 
MIP-1A 27.02±7.04 22.27±5.93 45.74±19.89* 28.52±9.83 0.018 
IL-4 23.18±11.93 29.70±14.74 31.21±11.22 35.39±10.58 0.3748 
IL-1B 126.22±90.19 20.06±16.42 67.74±71.77 54.67±64.93 0.1005 
IL-2 68.46±28.80 92.71±63.96 72.42±14.68 83.74±25.80 0.6546 
EGF 234.22±202.76 369.13±181.41 323.71±62.11 192.58±112.08 0.3922 
IL-10 62.56±37.53 38.97±24.24 57.93±57.56 57.75±41.47 0.8135 
IL12P70 69.77±26.86 82.26±38.17 103.65±34.89 89.89±32.31 0.3447 
INFY 96.21±49.15 128.52±48.54 145.08±87.45 101.58±61.76 0.5661 
IL-5 56.80±26.85 75.98±15.23 78.64±16.99 77.47±20.71 0.2062 
IL17A 29.62±7.34 37.78±14.70 39.32±16.55 38.64±10.97 0.535 
IL-18 506.12±138.40 312.26±297.23 472.82±228.10 350.87±145.14 0.3132 
MCP-1 475.58±51.96 776.67±114.72 741.03±250.03 748.33±291.64 0.0568 
IP-10 185.99±42.48 129.70±22.16* 166.04±44.34 173.19±17.32 0.0312 
GRO/KC 116.17±21.69 75.73±16.15 72.99±46.29 75.60±32.01 0.0702 
VEGF 54.01±12.05 52.53±13.22 56.39±9.94 62.53±14.70 0.4857 
FRACTALK
INE 
73.31±19.45 74.41±21.88 79.95±19.41 86.25±13.81 0.5796 
LIX 2914.53±183.04 2776.74±390.75 2552.78±585.48 2700.44±326.32 0.4544 
MIP-2 120.76±37.95 87.81±22.32 137.91±48.82 90.32±25.71 0.0382 
TNFA 6.72±3.38 9.96±4.30 11.17±4.12 11.45±3.05 0.1285 
RANTES 1984.74±534.73 1598.93±603.17 1696.66±667.23 1667.29±514.59 0.6658 
Table 4.3.  Cytokine levels after chronic administration with GRFT.  Cytokine levels in serum from 
rats 24 hours after treatment was quantitated.  Analytes with three or more positive signals per 
group: granulocyte colony-stimulating factor (G-CSF), Eotaxin, Granulocyte macrophage colony-
stimulating factor (GM-SCF), Interleukin 1 alpha (IL-1a), Leptin, Macrophage Inflammatory 
Protein 1 alpha (MIP 1-a), Interleukin 4 (IL-4), Interleukin 1 beta (IL-1B), Interleukin two (IL-2), 
EGF, Interleukin 13 (IL-13), Interleukin 10 (IL-10), Interluekin 12 (IL-12p70), Interferon gamma 
(INFy), Interleukin 5 (IL-5), Interleukin 17 alpha (IL-17A),  Interleukin 18 (IL-18), monocyte 
chemoattractant protein 1 (MCP-1), interferon gamma induced protein 10 (IP-10), growth-related 
oncogene (GRO/KC), vascular endothelial growth factor (VEGF), Fractalkine, lipopolysaccharide 
induced CXC  chemokine (LIX), macrophage inflammatory protein 2 (MIP-2), tumor necrosis 
factor alpha (TNFa), and Rantes. One-way ANOVA with Bonferroni post-test analysis indicating 








CHARACTERIZATION OF BIOCHEMICAL INTERACTIONS OF GRIFFITHSIN 
THROUGH DIFFERENTIAL SCANNING FLUORIMETRY, AFFINITY 
PURIFICATION, AND DIFFERENTIAL SCANNING CALORIMETRY  
INTRODUCTION 
 
GRFT is a 12.7 kDa carbohydrate binding protein derived from the red algae 
Griffithsia sp [32].  GRFT displays a strong affinity for N-linked oligomannose 
glycans (Man5-9GlcNAc2) constituting glycan shields of multiple viruses, making it 
a strong candidate as an antiviral microbicide and/or therapeutic [163, 164].  
Notable antiviral activity has been observed in the case of HIV-1, HCV, Herpes 
virus, SARS-CoV, and influenza [23, 30, 36, 171, 173].  Given this broad 
spectrum antiviral activity, research into GRFT’s suitability as a systemic antiviral 
prophylactic is ongoing.  Previous in vitro studies have demonstrated that GRFT 
possesses a favorable toxicity profile, suggesting its viability as a systemic 
therapeutic.  For example, GRFT is neither mitogenic, strongly immunogenic, nor 
a strong inducer of inflammatory cytokines in human peripheral blood 
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mononuclear cells [35, 169].  Further, previous studies into the impact of in vivo 
administrations of GRFT have also been promising.  GRFT shows in vivo activity 
against JEV, HCV and SARS-CoV in mouse models [23, 30, 31, 173]. GRFT was 
also tolerable in a 10-day acute subcutaneous administration study involving both 
mice and guinea pigs [34].   
          Recently, we confirmed that GRFT was tolerable over the course of a 55-
day chronic administration study in rats, with minimal systemic toxicity reported 
(manuscript in preparation).  Interestingly, in prior studies active GRFT 
concentrations were observable in treated mice and guinea pigs for many days 
(up to 14 days in mice) after subcutaneous administration[34].  An additional 
study into GRFT’s pharmacokinetics also displayed a rapid elimination or 
degradation of GRFT following subcutaneous or intravenous administration 
(manuscript in preparation).  However, in that study, active concentrations of 
GRFT were still detectable at potentially therapeutic levels up to 96 hours 
following systemic administration.  Given GRFTs observed serum persistence 
and its increasingly recognized potential as a systemic anti-viral therapeutic, 
further investigation into GRFT’s potential binding activity, binding partners, and 
serum interactions are necessary. 
          A number of methods exist which can elucidate potential protein-ligand 
interactions, potential protein-protein interactions, and changes in serum protein 
interactions, thus allowing full characterization of the protein of interest.  These 
include Differential Scanning Fluorometry, Affinity Purification, and Differential 
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Scanning Calorimetry.  We utilized these techniques to gain greater insight into 
GRFT’s potential interaction with endogenous proteins and ligands. 
Differential scanning fluorimetry (DSF) is useful to measure protein-ligand 
interactions.  DSF has been used to identify potential ligand interactions, 
including polysaccharide, peptide, and nucleic acid interactions with proteins, in a 
high-throughput manner [212-217]. Given that ligand binding can increase 
protein stability, shifts in fluorescence of hydrophobic dyes can be used identify 
specific binding [214]. In the presence of a ligand, increases in melting 
temperature (Tm) are observed which can yield data for identifying ligands which 
may bind to, and stabilize, the protein.  Thus DSF can screen for ligand binding 
interactions which tend to stabilize a protein.  Functionally, DSF measures the 
temperature at which a protein melts through the use of a fluorescent dye, such 
as SYPRO Orange, which possesses an affinity for hydrophobic regions of a 
protein [215].  This process, conducted with a PCR instrument in microplate 
format, provides for a high-throughput manner by which identification of specific 
protein-ligand interactions can be measured.   
Affinity Purification (AP) can identify stable protein-protein interactions.  One 
form, Tandem Affinity Purification has been used successfully to purify proteins 
for identification by Mass-Spectrometry [218-224].   In another type of AP, a 
recombinant “bait” protein is used to pull down proteins and protein complexes 
from biological samples, and these interacting proteins are identified 
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by Mass Spectrometry [225, 226].  While a number of tags have been identified 
for this process, FLAG tagging of a bait protein has been used in AP with 
success [221, 223]. 
Finally, differential scanning calorimetry (DSC) is a novel and effective 
method to explore endogenous protein interactions in serum or plasma. There 
are over 3000 different proteins in plasma or serum. However, the majority of the 
proteomic mass consists of 22 proteins, while all the others are in relatively very 
low abundance [227, 228]. DSC generates an excess specific heat capacity 
profile, represented as a thermogram, of the most abundant proteins present in 
plasma or serum[229]. These thermograms represent the weighted average of all 
the major serum proteins interactions [230].  Alterations in thermograms from a 
“normal” curve generated from healthy subjects represent changes in major 
serum protein interactions [231].  The interactome hypothesis holds that low 
molecular weight proteins or peptide binding to more abundant serum proteins 
can alter normal serum protein interactions and thermostability [232]. 
DSC has been used to identify significant differences between the healthy 
and disease thermograms in conditions such as rheumatoid arthritis, lupus 
erythematosis, and Lyme disease [229, 230, 233-235]. Furthermore, DSC has 
been proven to effectively identify changes in thermogram shapes indicative of 
degrees of disease state in cervical cancer [231].   Therefore, we hypothesized 
that DSC would be a useful additional tool in determining whether systemic 
GRFT administration alters endogenous serum protein interactions, which in turn 
could lead to identification of unseen toxicities associated with GRFT treatment. 
107 
 
By employing DSF, AP and DSC to study GRFT’s potential biochemical 
interactions, we have confirmed potential binding activity beyond oligomannose 
moieties, identified a number of putative serum binding partners in human serum, 
and demonstrated that GRFT spiked into rat serum in vitro does not appear to 
impact serum protein interactions.  However, calorimetric analysis of serum from 
prior in vivo experiments involving chronic subcutaneous administration of GRFT 
in rats revealed changes in serum thermograms.   These results suggest that 
protein and/or protein-glycan binding may be a mechanism by which GRFT 
persists in serum.  Further, GRFT by itself does not appear to perturb serum 
protein interactions.  However, it appears that GRFT administration in vivo may 
induce changes in serum protein binding interactions, though the mechanisms 














MATERIALS AND METHODS 
Lectin reagents  
Recombinant GRFT or GRFTlec- (a non-binding protein control in which 
lectin binding sites are eliminated) was produced in Nicotiana benthamiana as 
described previously, purified to >99% purity, and formulated in phosphate 
buffered saline (PBS), pH 7.4 [169]. 
 
Tandem Affinity Purification Lectin reagents 
Linear fusions of GRFT or GRFTlec- (a non-binding protein control in which 
lectin binding sites are eliminated) homodimers with a C-terminal FLAG tag and 
N-terminal 6xHis tag were cloned by a collaborator (manuscript in preparation) 
into Icon Genetics vector pICH11599. A three-component vector system was 
used for expression. Agrobacterium tumefaciens containing the gene of interest, 
integrase, and cytosolic were infiltrated into 28 d.p.s. (days post sowing) N. 
benthamiana plants. Five days after infiltration, treated N. benthamiana plants 
were harvested and ground in 20 mM sodium phosphate, 500 mM NaCl, 20 mM 
imidazole, ascorbic acid, sodium metabisulfite, 8M urea, pH 7.4 at 0.5g product 
per 1ml buffer. The extract was filtered over a 1 filter press and the subsequent 
cake washed with 25% volume of buffer. The extract was again filtered through a 
0.5 filter press and washed with 25% volume of buffer. To prepare for 
chromatography, extracts were filtered through a 0.2 bottle top filter and purified 
over nickel sepharose GE with a one-step elution gradient to 20 mM sodium 
phosphate, 500 mM NaCl, 250 mM imidazole, pH 7.4. Elution fractions were 
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The lectin binding capacity of GRFT and GRFTlec- was examined by using 
SYPRO Orange thermal shift assays.  Briefly, SYPRO orange (Sigma) was 
diluted to 400x concentration in PBS, pH 7.4.  GRFT and GRFTlec- were diluted to 
125 uM concentrations.  Serial dilutions of the following potential ligands were 
formulated in PBS: mannose, maltose, glucose, N-acetylglucosamine heparin, 
mannan, and alpha 1,2 mannobiose.   
 Samples for protein melt analysis were formulated using 29.05 µL of 
GRFT or GRFTlec-, 8.75 µL of diluted SYPRO orange, and 32.2 µL of ligand 
dilutions to yield at total volume of 70 µL sample.  20 µL of each sample were 
loaded in triplicate into a 96-well PCR plate (NUNC).   
 Samples were analyzed by an Applied Biosystems StepOnePlus real-time 
PCR system. Temperature range studied was 20C to 95ºC, incrementally raised 
0.2ºC/15 seconds. The effect of saccharide binding on protein melting was 
determined by changes in fluorescent signal as the sample was heated to 95ºC.  
Controls consisting of highest saccharide concentrations containing no GRFT or 






Affinity Purification – Human Serum 
 Affinity Purification of GRFT-protein complexes was facilitated by use of 
GRFT or GRFTlec- containing a His/FLAG tag as a “bait” protein. Briefly, 500 µL of 
Anti-FLAG M2 resin (Sigma) was loaded into 2 ml gravity flow columns (Fisher).  
Columns were equilibrated by running 5 column volumes of Tris Buffered Saline 
(pH 7.4) through the column resin.  For bait containing columns, 300 µg aliquots 
of FLAG-GRFT or FLAG-GRFTlec- protein was then run through respective Anti-
FLAG gravity columns a total of four times to ensure all FLAG fusion proteins 
were bound to the resin.  A resin-only control column was used to assess non-
specific resin binding. 
          Human serum (Innovo Research) was diluted five-fold in PBS and run 
through the column by gravity filtration.  After serum was run through the 
columns, the column resins were washed with 20 column volumes (40 ml) of 
TBS, pH 7.4.  Isolated proteins were eluted by the addition of 8mL of 0.1M 
glycine HCL pH 3.5, collected in 8, 1 ml fractions.  Each 1 ml fraction was 
collected in Eppendorf tubes containing 10 µL of 1 M Tris-HCL pH 9.0.  Columns 
were re-equilibrated by running 10 column volumes of TBS pH 7.4 through the 
column.  Elution fractions were analyzed for protein content by Nanodrop.  The 
highest protein containing fractions were analyzed by Mass Spectrometry.   
Proteins in selected elution fractions were identified by ElectroSpray 
ionization, liquid chromatography and tandem mass spectrometry (Mary 
Gawinowicz).  Briefly, 100 µL of sample was combined with 200 µL 8M urea in 
0.1M Tris-HCl, pH 8.5.  Diluted sample was then added to the filter unit of a 
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Microcon YM-10 cartridge (Millipore) and centrifuged at 14,000 x g for 10 
minutes.  250 µL of 8M urea in 0.1M Tris-HCl, pH 8.5, was added to the filtration 
unit and centrifuged again. The final volume of the sample was 40 µL. The flow 
through was discarded. The concentrated sample in the filter unit was diluted 
with 60 µL 8M urea in 0.1M Tris-HCl, pH 8.5 and 10 µL of 0.1M DTT added. The 
solution was kept at 60°C for 1h and then cooled to room temperature.  The 
sample was alkylated by adding 10 µL of 0.15M iodoacetamide. The reaction 
was allowed to proceed in the dark for 30 minutes. The sample was then diluted 
with 100 µL 1M urea in 0.1M Tris-HCl, pH 8.5 and centrifuged at 14,000g for 10 
minutes, followed by another addition of the same buffer and centrifugation at 
14,000g. The process was repeated once. The remaining sample solution in the 
filter unit was collected and diluted to 50 µL with 1M urea in Tris-HCl, pH 8.5. 
Trypsin (Roche Biochemicals, sequencing grade), 0.2 µg in 20 µL 0.1M Tris-HCl, 
pH 8.5, was added and the solution incubated at 32°C overnight. The digested 
solution was desalted with a C18 tip and dried in a Speed-Vac concentrator. The 
digest was redissolved in 20 µL 0.2% formic acid and 5 µL injected onto the LC-
MS. 
LC-MS/MS was conducted on a Waters Q-Tof Ultima hybrid 
quadrupole/time-of-flight mass spectrometer with a nanoelectrospray source. 
Capillary voltage was set at 1.8kV and cone voltage 32V; collision energy was 
set according to mass and charge of the ion, from 14eV to 50eV. 
Chromatography was performed on an LC Packings HPLC with a C18 PepMap 
column using a linear acetonitrile gradient with flow rate of 200 nl/ min.  
112 
 
Raw data files were processed using the MassLynx ProteinLynx software 
and .pkl files were submitted for searching at www.matrixscience.com using the 
Mascot algorithm. 
 
DSC- Rat Serum Spiking 
For generation of rat serum thermogram profiles after spiking with PBS or 
GRFT, the protocol for sample preparation and dialysis described by Garbett et 
al. was used [231].  Briefly, a standard phosphate dialysis buffer (1.7 mM 
KH2PO4, 8.3 mM K2HPO, 150 mM NaCl, 15 mM  Na3C6H5O7, pH 7.5) was 
formulated and rat serum was dialyzed for a period of 24 hours at 4ºC to 
normalize buffer conditions.  Serum was thawed overnight at 4ºC the night before 
dialysis.  After thawing, 100 µL aliquots of rat serum (Sigma) and an aliquot of 
100 µL of 10.8 mg/ml GRFT were loaded into Slide-A-Lyzer mini-dialysis units 
(MWCO 3500; Pierce, Rockford, IL) and dialyzed  at 4ºC against 1L of buffer with 
changes occurring at 3 hours, 7 hours, 11 hours, and overnight.  Following 
dialysis, serum was filtered through a Spin-X centrifuge 0.45 micron centrifuge 
tube filter and 99 µL aliquots were made for spiking with GRFT or PBS. Final 
dialysis buffer, to serve as a reference and diluent for sample dilutions, was 
filtered using a 0.2 µm rapid flow filter and stored at 4°C.   
Dialyzed GRFT dilutions in PBS were prepared ranging from 10,000 nM to 
50 nM.  Dialyzed serum aliquots were spiked with GRFT or PBS by the addition 
of 2 µL of GRFT dilution or PBS to 98 µL of dialyzed serum.  The resulting final 
concentrations ranged from 1 nM to 1000 nM, to exceed the upper molarities of 
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GRFT concentrations previously observed after subcutaneous dosing in prior 
studies [34]. Samples were allowed to react at 4ºC for one hour.  Spiked serum 
samples were diluted in dialysis buffer (1:25) and samples and reference 
diasylates were loaded into a 96-well plate and loaded into the instrument 
autosampler thermostatically set at 4ºC.  
DSC data were collected with a NanoDSC (TA Instruments).  Scans were 
recorded from 20ºC to 100ºC at a scan rate of 1c/ per minute.  Duplicate scans 
were obtained for all samples.  Excess specific heat readings for samples and 
reference buffers were recorded.    Baseline corrected scans were obtained by 
subtracting a suitably adjacent reference buffer-buffer scan from the raw scans.  
Scans were further normalized for total protein concentration.  Total protein 
concentrations were determined using Pierce bicinchoninic acid protein assay 
key and modified microplate procedure.  Scans were corrected for non-zero 
baselines using Origin 7 for linear baseline fitting. Interpolated, final thermograms 
were calculated and average scans calculated from the duplicates were plotted 
as excess specific heat capacity versus temperature. 
 
DSC – Chronically Dosed Rat Serum 
In a previous study (manuscript in preparation), age-matched Sprague 
Dawley rats were subcutaneously treated with either PBS or 10mg/kg GRFT 
every three days for 51 days.  A group of passively-immunized animals also 
received 1.4 mg of anti-GRFT Ig formulated in 1 ml of PBS every 14 days.  
Additionally, one group animals was pre-immunized for 6 weeks prior to the study 
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with GRFT and Sigma adjuvant to prime an immune response to GRFT prior to 
treatment initiation. Blood was drawn via lateral tail vein on the following days: 
Day 10, 24, 38, and 52, with sacrifice on day 55 via CO2 asphyxiation followed by 
cardiac puncture exsanguination. Serum was separated from blood samples 
following coagulation by centrifugation and stored at -20ºC until needed. Given 
the timing of blood draws in relation to last administration of GRFT or PBS, Bleed 
1(day 10) and Bleed 4 (day 52), both 24 hours after administration, were selected 
for calorimetric analysis. 
As described previously, samples were thawed at 4ºC overnight before 
dialysis.  Samples were dialyzed into standard phosphate buffer for 24 hours with 
four buffer changes.  Following dialysis, serum samples were diluted in dialysis 
buffer (1:25) and excess specific heat readings at temperature ranges from 20°C 
to 100°C were determined.  Duplicate runs were completed and average 




 Preliminary examination of DSF curves revealed a dynamic range of 45-
95ºC.  Accordingly scans were truncated to this range for all analysis.  Melting 
transition temperatures (Tm) for each curve was determined using GraphPad 
5.01 and Boltzmann Sigmoidal non-linear fit template available at 
ftp://ftp.sgc.ox.ac.uk/pub/biophysics/GraphPad_templates/.  Mean Tm values for 
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GRFT and GRFTlec- were determined for pure protein and each ligand 
concentration. 
 Proteins recovered by AP were identified by Mascot algorithm.  However, 
not all proteins identified were deemed a reliable “hit”.  Proteins identified were 
filtered by both Mascot score and number of “significant” ion matches to increase 
positive identification confidence. Given that a significant peptide ion match could 
appear in more than one protein, a minimum of 3 significant (p<0.05) peptide ion 
matches for a particular protein identified and a minimum Mascot score of 90 
were used as thresholds for filtering.  Proteins identified were grouped by bait 
protein used (FLAG-GRFT, FLAG-GRFTlec-, or resin-only). 
 Preliminary examination of DSC thermograms revealed a dynamic 
temperature range of 45 to 90ºC for the serum thermogram curves.  Accordingly, 
scans were truncated to this range for all analysis.  Quantitative comparisons of 
the thermograms were accomplished through calculation of shape and feature 
metrics as well as selection of points of interest within the dynamic range of the 
thermogram curve.  Parameters considered included: total area under the curve 
(AUC), maximum curve height (Cp
ex), temperature at max height (Tmax) Curve 
width at half height (width), maximum peak height at the 60-67C range (Cp
ex1), 
maximum peak height of the secondary peak at the 68-72C range (Cp
ex2), and 
ratio of the first and second peak amplitudes, and first moment temperature (Tfm). 
The first moment temperature (Tfm), used to analyze geometric area distribution 
changes, was calculated as described by Garbett [231]. Additionally, excess 
specific heat capacities were analyzed for the following temperature points: 55, 
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60, 65, 67, 70, 75, and 80ºC.  Finally, a composite 'similarity metric' developed by 
a collaborator (Dan Fish) was generated for each curve [234]. This metric is a 
combination of an average z-scores or p-values for all temperature points, 
assuming a normal distribution of the control curve, and a correlation measure, 
allowing a comparison of test curves versus an average control curve.  Similarity 
scores for each curve were generated.  Mean similarity scores were then 
analyzed by one-way ANOVA with Bonferroni posttest analysis to determine 
which groups were changed, if any. 
Thermogram parameters were grouped by treatment group and 
differences in thermograms were assessed by ANOVA with post-test to identify 
changes in groups. A p-value of <0.05 was deemed significant.  Statistical 
analysis was conducted using GraphPad 5. 
For Day 52 thermogram parameters, correlations between certain curve 
parameters and serum data previously seen for Day 55 terminal bleeds (Barton) 
of the same animals were evaluated. Pearson Correlation Coefficients and p-











Ligand free, protein-only controls consisting of GRFT or GRFTlec- 
displayed marked differences in melting profiles, with   GRFT’s Tm at 
approximately 75.65ºC   and  the Tm for GRFT
lec- at approximately 80.68ºC 
(Figure 5.1, Table 5.1).   
 Further differences in GRFT and GRFTlec- fluorescence signals were 
observed in response to varying ligand concentrations (Figure 2).  GRFT 
displayed substantial shifts in melting temperature in response to 460 mM 
concentrations of glucose, maltose, mannose, and N-acetyl glucosamine with 
shifts in Tm from 9 to 11ºC (Figure 5.2 and Table 5.1).  Furthermore, GRFT 
displayed shifts of >1ºC in melting temperature at 46mM concentrations of those 
saccharides as well as 2.3 mg/ml and 230 µg/ml concentrations of mannan 
(Figure 5.2B and Table 5.1).  In contrast, high concentrations of all ligands 
shifted the melting temperatures for GRFTlec- by less than 2ºC (Table 5.1).  




Purification of human serum proteins using FLAG-GRFT and FLAG-
GRFTlec- bait proteins was successful, though the majority of the proteins 
identified were Ig chains or albumin.  MS/MS analysis of the elution fractions 
revealed a number of proteins were retrieved from human serum. After 
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eliminating keratinocyte-related proteins and filtering by Mascot score and >2 
significant peptide ion hits, a number of candidate binding partners for each 
purification condition were identified (Table 5.2).  Designating and Eliminating 
proteins bound to resin as nonspecific background revealed proteins/protein 
complexes interacting with FLAG-GRFT, FLAG-GRFTlec-, as well as both FLAG-
GRFT and FLAG-GRFTlec- (Table 5.3). 
 
DSC - GRFT and PBS spiked rat serum    
 Rat sera spiked with varying concentrations of GRFT did not display a 
substantial shifts in thermograms versus PBS-spiked control serum. (Figure 5.3).   
 
DSC– Chronically Treated Rats  
 Mean treatment group thermogram curves were generated for bleed 1 
(day 10) and bleed 4 (day 52) (Figure 5.4A and B, respectively).  Standard 
deviation of mean group thermograms from both time points were generated for 
visual inspection. (Figure 5.4C and D) Analysis of thermogram area (Figure 
5.5A), max height (Figure 5.5B), Tmax (Figure 5.5C), or peak ratios (Figure 5.6C) 
did not reveal any significant differences between groups on either day 10 or day 
52.  Further, peak heights were not significantly different among groups at day 10 
(Figure 5.6A).  However, differences were observed in Width, Cp
ex1, and Tfm for 
day 52 curves.  Day 52 widths were significantly different (p=0.0266), with both 
pre-immunized and passively immunized animals displaying smaller widths in 
comparison to PBS-treated controls (Figure 5.5D).  Cp
ex1 heights in the 60-68ºC 
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range were also significantly different for day 52 samples, with passively 
immunized animals displaying a significantly decreased (p=0.0389) maximum 
peak height in that temperature range (Figure 5.6B).  Finally, Tfm were 
significantly reduced in GRFT treated groups vs. PBS treated controls (Figure 
5.6D, p=0.0179). 
 Analysis of group excess specific heat capacities at selected temperatures 
did not reveal any differences among the groups at day 10 (Figure 5.7A).  
However, day 52 groups were significantly different at both the 67ºC (p=0.03) 
range as well as the 75ºC temperature (p=0.004).  (Figure 5.7B). 
 Overall curve similarity scores did not reveal significant differences among 
treatment groups on day 10, though results did approach significance (Figure 8).  
However, significant differences between groups were observed on day 52 
(p=0.0069).  Which? Post-test analysis revealed significant differences in both 
GRFT and passively-immunized groups in relation to PBS-treated controls. 
Pearson correlation analysis among day 52 curve parameters and day 55 
serum characteristics revealed both significant positive and negative correlations 
(Table 5.4).  Significant positive correlations were observed between the 
following parameters (correlation coefficient, p-value): Albumin and Total Protein 
(0.85,p<0.0001), Area and Width (0.44, p=0.0321), Area and Max Peak(0.92, 
p<0.0001), Globulin and Total Protein (0.49, p=0.0189), Globulin and Anti-GRFT 
antibody titers (0.45, p=0.0375), Globulin and Tfm (0.50, p=0.0145), and Tmax and 
Tfm (0.52, p=0.0095).  Significant negative correlations were observed between: 
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Albumin and Anti-GRFT antibody titers  (-0.50, p=0.0188), Width and Tfm (-0.56, 

























Potential protein and ligand interactions can be of physiological relevance 
for a new therapeutic.  Accordingly, identification of interaction potential can be 
useful.  DSF analysis of both GRFT and GRFTlec- showed differences in melting 
points as well as differences in binding of various saccharides.  Analysis of 
fluorescence curves showed that ligand-free GRFT displayed a consistent 
melting transition temperature at approximately 75 degrees, whereas GRFTlec- 
displayed a melting temperature of approximately 80 degrees (Table 5.1).  This 
difference in melting temperature given the modest changes to the protein would 
suggest that ablation of lectin binding sites result in increased protein stability, an 
effect also generally theorized to occur when protein binding sites are occupied 
by ligand [212, 214].   
Positive shifts in melting temperature as a result of saccharide binding 
with GRFT and GRFTlec- were also observed.  Ligand binding to a protein’s active 
site will normally increase stability, leading to increase the protein melting 
temperature.  Accordingly it was expected that specific saccharide binding to 
GRFT’s lectin binding sites would result in higher transition temperatures.  This 
was confirmed by the marked increases in melting temperatures of GRFT upon 
addition of glucose, maltose, mannose, mannan, and N-acetylglucosamine.  
While of much lower affinity than oligomannose, interactions between GRFT and 
these carbohydrates have been observed in other studies [164, 166].  Although 
GRFT binds strongly to oligomannose glycans [163] via its jacalin-like 
carbohydrate binding sites, weaker or transient interactions with other 
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endogenous saccharide moieties cannot be ruled out and may help to explain 
GRFT’s long serum persistence observed in other studies [34].  Further, similar 
marked differences in melting temperature was not observed for GRFTlec- for all 
saccharide concentrations.  While GRFTlec- displayed a higher baseline melting 
temperature, it only displayed a modest (<2ºC) shifts in melting temperature at 
the highest saccharide concentrations.  This is in stark contrast to the greater 
(>9ºC) shifts observed in GRFT at comparable concentrations.   These data 
confirm that a range of weaker potential saccharide binding partners for GRFT 
exist and may be relevant to GRFT’s serum stability.  Interestingly, high heparin 
concentrations decreased GRFT’s Tm, suggesting some level of destabilizing 
effect.  However, how and why this destabilization occurs is currently unknown.  
In addition to interacting with saccharide moieties, GRFT’s ability to 
effectively bind to human serum proteins was confirmed by its interaction in the 
FLAG-GRFT serum capture columns. While some off-target serum binding was 
observed in the resin-only serum capture, a number of unique proteins, including 
lipoprotein and complement proteins, were captured by FLAG-GRFT bait.  
Further, FLAG-GRFTlec-, also captured a number of proteins, including some that 
were unique to GRFTlec-.   FLAG-GRFT and FLAG-GRFTlec- differ only in the 
lectin binding motifs, therefore capture of unique serum proteins by FLAG-GRFT 
indicates a binding mechanism which requires active lectin binding sites. We 
hypothesize that those proteins captured by both FLAG-GRFT and FLAG-
GRFTlec- may suggest alternative, non-lectin mediated binding mechanisms or 
binding of the serum proteins to structural motifs on the bait proteins.  However, 
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the specific nature of each protein’s interaction will need further investigation. 
Additionally, a SwissProt search of post translation modifications typical to the 
recovered serum proteins also revealed a varying number of N-linked glycans 
present on the proteins.  However, the vast majority of glycans noted were of the 
N-linked, complex variety.   These data, together with saccharide binding data 
from DSF, indicates that GRFT binds an array of serum proteins, and is not 
limited to those possessing oligomannose glycans.   
Interestingly, a larger percentage of proteins bound exclusively by GRFT 
were complement proteins and apolipoproteins, attractin, and vitronectin.  The 
mechanism of these binding interactions will need to be confirmed by other 
binding methods to determine whether they are recovered as a part of a 
complex, however based upon their exclusive recovery by the FLAG-GRFT 
column, it appears that they will likely involve the lectin binding sites of GRFT.  
For instance, the presence of proteins possessing no N-linked glycans, as in the 
case of Apolipoprotein A-II is suggestive of entire protein complexes being 
precipitated from serum via this method.  Interestingly, despite apparent binding 
activity with apolipoproteins, cholesterol changes in guinea pigs and rats have 
not been noted [34] (and manuscript in preparation).  Further, given continued 
antiviral activity observed in serum following systemic administration[34] (and 
manuscript in preparation), it does not appear that this binding interaction 
substantially impairs GRFT’s antiviral activity.  However, complement interactions 
may be problematic.  Complement proteins are important in the innate immune 
response to pathogens.  Accordingly, a binding interaction with these proteins 
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could have deleterious effects if it binds in a manner so as to inhibit pathogen 
recognition or cause functional deficiency of particular complement proteins [236-
240].  For instance, deficiencies in complement 2 and 4 have been associated 
with autoimmune diseases, particularly systemic lupus erythematosus [240-242].  
Whether these binding interactions cause functional depletion or complement 
activation will require further study.  However, it is entirely possible that this 
binding activity may be related to the potential immunosuppressive and anti-
inflammatory effects of GRFT observed in previous long term systemic studies of 
GRFT in rats. 
GRFT’s long serum persistence has been observed in our prior studies. It 
is believed that these protein-protein interactions may be crucial in maintaining a 
baseline serum concentration of GRFT.  Further enhancing these interactions 
may be useful in exploring GRFT’s potential as a long-term systemic pre-
exposure prophylactic.   
 Calorimetric analysis of spiked rat serum and analysis of samples from a 
GRFT chronic dosing study in rats also yielded notable results.  Spiking large 
concentrations of GRFT into rat serum did not appreciably change serum 
thermograms in comparison to the PBS spiked controls (Figure 5.3).  This would 
seem to indicate that GRFT’s presence by itself does not disturb major serum 
protein interactions.  However, thermograms of sera from animals chronically 
treated differed depending on the duration of GRFT treatment (Figure 5.4A). Both 
visual inspection of mean thermogram curves and statistical analysis consistently 
showed no significant differences on day 10 other than first moment 
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temperatures.  Notably, Bonferroni post-test analysis failed to identify which 
groups were different.  However, passively and pre-immunized animals displayed 
lower mean Tfm than PBS treated controls.  It is hypothesized that these first 
moment temperature decreases would indicate an increase in overall area at 
lower temperature ranges, possibly by a greater contribution to area of the mean 
curve by immunoglobulins (as elevated IgG levels was the aim of pre-
immunization, and the effect of passive immunization).  Further study will be 
necessary to see if this redistribution of curve area was due to an increase in 
IgG, IgM, or some other immunoglobulin in those treatment groups. 
 In stark contrast with day 10 samples, significant changes were induced 
by day 52.  Visual examination of the mean group thermograms revealed notable 
differences and statistical analysis of day 52 curve parameters revealed multiple 
changes in treatment group thermograms vs. PBS-treated controls. Categories 
such as Width, Cp
ex1, and Tfm were significantly different among treatment 
groups, which could indicate stabilizing protein interactions with major serum 
proteins, shifting the area of the curve to higher temperatures while narrowing the 
width of the curve. Stabilization of serum proteins is thought to result in an 
increased shift of their melting to higher temperatures.  A destabilization of 
endogenous serum protein interactions should result in shifting of thermograms 
to lower temperatures.  Of the serum parameters examined for day 52 samples, 
GRFT-only treatment appeared to result in a downshift of Tfm not observed in 
other groups, suggesting a destabilizing alteration of serum protein interactions.  
Further, the Tfm did not display a similar shift in pre-immunized or passively 
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immunized animals at that time point.  Nonetheless, those groups did display 
changes in width, with passively immunized animals also displaying a decrease 
in Cp
ex1.  Analysis of excess specific heat capacities at specific temperatures 
revealed few differences, with the only changes seen between Passively 
Immunized/GRFT-treated animals vs PBS controls at 67ºC and 75ºC, and a 
difference between GRFT-treated vs. PBS controls also observed at 75ºC.   
The broadest measure of differences between groups appeared to be 
accomplished by the generation of similarity scores relative to a mean control 
curve.  Day 10 curves differences approached significance, with GRFT-only and 
GRFT/passively immunized curves displaying the greatest degree of difference 
versus mean controls.  However, by Day 52, the differences are much more 
substantial.  Similarly to day 10, GRFT-only and GRFT/Passively immunized 
groups displayed very significant changes vs. PBS-treated controls.  This 
difference is not observed in the group which was pre-immunized with GRFT and 
adjuvant prior to initiation of treatment.  Further, in both cases, similarity scores 
for pre-immunized animals revealed greater similarity to controls than either 
GRFT or GRFT/passively immunized groups.  As such, it would appear that pre-
immunization or priming of an immune response may blunt some of the 
alterations in serum protein interactions.  Prior studies have suggested that de-
immunization of GRFT may be necessary to eliminate some of the changes 
induced by systemic administration of GRFT [34, 161, 162].  However, these 
data suggest that an immune response to GRFT may be protective of the 
changes induced by systemic administration of the protein. 
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Finally correlation analysis between selected day 52 curve parameters 
and serum parameters from the same animals bled at day 55 revealed a number 
of significant positive and negative correlations.  These correlations assumed 
non-rapid alteration of serum protein interactions over the intervening 3 day 
period, and were necessary given exhaustion of day 52 and day 55 serum for 
analysis.  In many instances, correlations between total globulins, albumin, and 
total protein were expected.  Further, these correlations revealed increases in 
globulin positively correlated with increased in Tfm.  However, no curve parameter 
significantly correlated with anti-GRFT activity determined by antibody titer in a 
previous study. 
In conclusion, DSF and AP confirms that GRFT is capable of binding 
saccharide moieties and proteins beyond those displaying high-mannose 
(oligomannose) glycans [164, 166]. Further, in some instances, it appears that 
GRFT may use lectin-binding sites to bind to endogenous serum proteins, 
potentially through binding to other types of N-linked glycans.  However, it is also 
wholly possible that in some instances, GRFT is the “prey”, given the number of 
proteins captured by both GRFT and GRFTlec-.  These interactions may prove to 
be the foundation of GRFT’s long serum persistence and further study may yield 
insights into how GRFT’s serum persistence could be extended without the 
sacrifice of anti-viral activity.  Additionally, DSC results have shown that while 
chronic GRFT administration has been observed as tolerable in other studies, 
alterations to endogenous serum protein interactions may result as a 
consequence of longer-term chronic treatment.  However, these alterations do 
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not appear to be due to the simple addition of GRFT into the system.  These 
results would indicate that GRFT administration results in an 
induction/suppression of other proteins, alterations in the binding of lower 
molecular weight proteins to the more abundant proteins, or alteration of higher 
abundance protein proportions, to which DSC is extremely sensitive.  Of note, 
while still altered to a degree, animals pre-immunized with GRFT and adjuvant 
consistently displayed less thermogram variation in contrast to GRFT-only or 
GRFT/passively immunized treatment groups.  This would seem to suggest a 
protective immunological response, beyond simple production of 
immunoglobulins.  Further, based on prior findings, that response does not 
appear to compromise antiviral activity.  However, further study into exactly how 
these changes are induced, as well as which proteins interactions are altered, 










Figure 5.1.  GRFT and GRFTlec- SYPRO orange denaturation curves in the 
absence of saccharide ligand.  Ligand-free fluorescence curves generated by 





























Figure 5.2.  Protein stabilization effects of ligand binding on GRFT and GRFTlec-.  
Fluorescence curves of GRFT and GRFTlec- in the presence of potential ligands 





Table 5.1.  Concentration dependent shifts in melting temperatures of GRFT and 
GRFTlec- determined by SYPRO orange fluorescence shifts.  Tm values, 
representing melting temperatures for GRFT and GRFTlec- were determined in 
the absence and presence of ligands.  Tm change values were calculated for all 








Table 5.2.  Proteins recovered from Human Serum by Affinity Purification with 
FLAG-fusion protein.  Proteins recovered by affinity purification with Anti-Flag 
resin, FLAG-GRFT, or FLAG-GRFTlec- were identified by tandem mass 
spectrometry and filtered by MASCOT score and >2 significant peptide ion hits. 
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8N Alpha-1-antitrypsin 3N 
Apolipoprotein 
A-II 





Apolipoprotein D 2N Serotransferrin 3N,1O C4b-binding protein 
alpha chain 
3N 
Attractin 26N   Complement C3 3N 





4N,1O   Haptoglobin 4N 
Vitronectin 3N   Haptoglobin-related 
protein 
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Table 5.3.  Unique proteins identified by affinity purification.  Proteins were 
recovered by affinity purification using Anti-FLAG resin, FLAG-GRFT, and FLAG-
GRFT.  After filtering by Mascot score and >2 significant peptide ion hits, 
background binding was determined by proteins binding to Anti-FLAG resin-only 
controls. After elimination of proteins non-specifically binding to Anti-FLAG resin,  
a number of proteins unique to FLAG-GRFT or FLAG-GRFTlec- were identified. 





Figure 5.3.  Thermogram profiles of rat serum spiked with varying concentrations 
of GRFT.  Thermogram profiles of excess specific heat capacity versus 
temperature for rat serum spiked with a range of concentrations of GRFT.  
Concentrations were final molarity concentrations of GRFT spiked into rat serum 










Figure 5.4. Mean thermograms generated from sera from rats chronically treated 
with Griffithsin or PBS.  Mean thermogram profiles of excess specific heat 
capacity (cal/°C.g) versus temperature for Day 10 (A) and Day 52 (B) serum 
samples from animals chronically treated with PBS, GRFT, Pre-
Immunized/GRFT-treated [Pre-imm], or Passively Immunized/GRFT-treated 
[Pass-Imm].  Standard Deviation of excess specific heat capacity of each group 





Figure 5.5.  Thermogram shape and feature parameters for rats chronically 
treated with GRFT or PBS.  Values for Area (A), Height (B), Temperature at max 
height (C), and curve width (D) were calculated for each thermogram generated 
from serum from PBS [P], GRFT [G], Pre-immunized/GRFT-treated [Pr] and 
Passively-immunized/GRFT-treated [Pa] animals.  Mean values for treatment 
groups determined for treatment day 10 and 52 were analyzed by one-way 
ANOVA with Bonferroni posttest.  Bars represent mean and standard deviation of 







Figure 5.6.  Peak and First-moment (Tfm) thermogram parameters for rats 
chronically treated with GRFT or PBS.  Values for Peak Heights on day 10 (A), 
Peak heights on day 52 (B), Peak Ratios (C), and first moment temperatures (D) 
were calculated for each thermogram generated from serum from PBS [P], GRFT 
[G], Pre-immunized/GRFT-treated [Pr] and Passively-immunized/GRFT-treated 
[Pa] animals.  Mean values for treatment groups determined for treatment day 10 
and 52 were analyzed by one-way ANOVA with Bonferroni posttest.  Bars 
represent mean plus standard deviation of six biological replicates.  A p-value of 







Figure 5.7.  Distribution of Excess specific heat capacity for rats chronically 
treated with GRFT or PBS at select temperature points.  Excess specific heat 
capacities on day 10 (A) and day 52 (B) for animals treated with PBS [P], GRFT 
[G], Pre-immunized/GRFT-treated [Pr] and Passively-immunized/GRFT-treated 
[Pa] at 55, 60, 65, 67, 70, 75, and 80ºC were determined.  Whiskers indicate 
Maximum and minimum values.  Mean values were analyzed by one-way 
ANOVA with Bonferroni posttest.  A p-value of p<0.05 was considered significant 







Figure 5.8.  Thermogram similarity scores for sera from rats chronically treated 
with PBS or GRFT. Similarity scores were calculated for each thermogram 
generated from serum from PBS [P], GRFT [G], Pre-immunized/GRFT-treated 
[Pr] and Passively-immunized/GRFT-treated [Pa] animals by statistical 
comparison of curves versus a time-matched, mean PBS-treated control curve.  
Mean similarity values for day 10 and 52 similarity scores were analyzed by one-
way ANOVA with Bonferroni post-test.  Bars represent mean plus standard 
















TITER  WIDTH TMAX GLOB T.P 
MAX 
PEAK AREA 
ALB. 0.02 -0.06 -0.50 0.13 0.34 -0.07 0.85 -0.27 -0.13 








0.28 0.04 -0.19 -0.08 0.35 0.49 
   
GLOB. 0.50 0.12 0.45 -0.46 0.20 
    
TMAX 0.52 -0.32 -0.05 -0.10      
WIDTH -0.56 -0.02 -0.05 









        
 
Table 5.4.  Pearson Correlations of rat serum thermogram parameters and rat 
serum characteristics.  Day 52 thermogram parameters of Area, Max Peak, Tmax, 
Tfm, and Width were compared with day 55 serum characteristics of Albumin, 
Globulin, Total Protein (T.P), Anti-GRFT antibody titers, and pseudovirus 
neutralization (Psv. Neut.) from the same animal.  Pearson Correlation and p-
values were generated. A correlation having a p-value of p<0.05 was considered 

















SUMMARY OF GRFT RESEARCH AND IMPLICATIONS FOR FUTURE 
RESEARCH 
 
Throughout this work, we have analyzed GRFT’s biochemical interactions 
and physiological profile in furtherance of our overarching hypothesis that GRFT 
is a good candidate for antiviral prophylactic and therapeutics.  A number of 
hypotheses were explored.  First, we hypothesized that GRFT would be orally 
bioavailable after oral dosing.  To test this hypothesis, we performed 
pharmacokinetic testing as well as chronic oral dosing of GRFT.  Next, we 
hypothesized that chronic treatment of GRFT would be systemically tolerable.  
To test this hypothesis, we conducted a 51 day treatment regimen with GRFT in 
the presence and absence of a pre-existing immune response.  Finally, given 
data from prior experiments, we hypothesized that biochemical interactions of 
GRFT may include specific binding interactions of importance.  Further we 
hypothesized that while GRFT treatment did not cause significant toxicities in 
prior studies, perturbations in endogenous serum binding proteins may occur.  To 
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test these hypotheses, we conducted DSF, affinity purification of serum proteins, 
as well as DSC analysis of serum from chronically treated rats.  From the data 
presented in this work, a number of conclusions can be drawn, which taken as a 
whole, support the further study of GRFT as a systemic antiviral therapeutic. 
GRFT persisted in the circulation similarly upon dosed subcutaneously and 
intravenously. 
Pharmacokinetic studies of GRFT’s elimination profile revealed a number 
of insights into GRFT’s serum parameters.  First, GRFT does not appear to be 
extensively distributed in body water following intravenous administration.  
Second, GRFT displays a multi-phasic half-life, with half-life increasing after a 
very rapid elimination phase. GRFT concentrations 8 hours after either 
subcutaneous or intravenous administration were comparable, suggesting that in 
non-emergency settings, subcutaneous dosing may be a viable self-
administration method.  Regardless, physiologically relevant concentrations 
GRFT persisted for up to 96 hours in serum whether dosed intravenously or 
subcutaneously. 
Active GRFT is rapidly excreted by the kidneys, though proteolytic degradation 
may be occurring. 
Studies into the method of elimination displayed a strong excretion of 
active GRFT concentrations immediately following intravenous dosing.  However, 
over a 24 hour period, this fraction of GRFT excreted only accounted for 
approximately 1-2% of all GRFT dosed into the system.  Based upon studies of 
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others detailing GRFT’s generally strong proteolytic resistance, yet susceptibility 
to specific proteases, it is hypothesized that rapid protein degradation of free 
GRFT may be occurring. 
GRFT is not orally bioavailable at a detectable extent. 
Both single oral dosing and 10-day chronic oral dosing revealed GRFT is 
not orally bioavailable to a detectable level.  A single oral dose of GRFT, tracked 
at 8 time points after oral administration failed to yield detectable concentrations 
of GRFT in either serum or urine.  Further, a 10-day chronic oral dosing study 
was conducted, to account for the possibility of an accumulation effect.  All 
animals in that study, in which animals were orally administered by gavage with 
GRFT at two concentrations, failed to display detectable GRFT concentrations in 
serum at either day 5 or 3 hours after dosing on day 10.  These results would 
confirm that orally dosed GRFT is incapable of achieving potentially therapeutic 
concentrations in serum.   
GRFT is a potential orally dosed rectal microbicide. 
Despite studies showing GRFT is not orally bioavailable in rats, active 
GRFT concentrations were found in fecal material of rats orally dosed with 
GRFT.  These concentrations were dependent upon amount of GRFT orally 
dosed.  These GRFT concentrations, however, were only a very small fraction of 
GRFT dosed.  Nonetheless, fecal extracts prepared from fecal pellets displayed 
strong neutralization activity in HIV-env pseudovirus neutralization assays.  
Accordingly, it appears that a fraction of active GRFT can pass through the 
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digestive system intact.  Given the site of many HIV infections are in the rectal 
mucosa, oral dosing of GRFT may be a method of delivering active, potentially 
protective concentrations of the protein to the rectal mucosa.   
GRFT is tolerable in sub chronic dosing. 
Subcutaneous dosing of GRFT every 3 days was tolerable over a 51 day 
period.  No changes were observed in CBC values, body weights, or weight gain.  
Further, pathologist review of organ slides did not reveal any treatment related 
pathologies.  There were alterations in kidney weights with pre-immunized 
animals. Further, alterations in some serum chemistries and cytokine levels were 
observed.  However, varying form of immune response (pre or passive 
immunization) did not affect GRFT concentrations in serum or HIV-env 
pseudovirus neutralization activity.  Accordingly, GRFT would appear to be 
systemically tolerable for intermediate term usage as an antiviral prophylactic or 
therapeutic. 
GRFT treatment can induce changes in serum proteome with chronic dosing. 
Calorimetric analysis of serum protein interactions displayed changes over 
time associated with GRFT treatment.  At day 10, visual inspection of serum 
thermograms revealed fairly analogous mean thermograms for all treatment 
groups.  Furthermore, no changes were observed in any curve parameter other 
than First moment temperature (Tfm).  In that group, pre-and passively immunized 
animals displayed a mean Tfm lower than PBS or GRFT treated groups.  
However, by day 52, there were significant alterations in treatment group 
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thermograms in comparison to PBS-treated controls.  Many parameters analyzed 
revealed differences among groups, including passively-immunized and GRFT 
treated groups.  However, it appeared that pre-immunization was able to blunt 
alterations in parameters.  Pre-immunized groups were not generally statistically 
different in their curve parameters versus PBS-treated controls.  This would 
seem to indicate a protective effect of an immune response associated with 
GRFT treatment. 
GRFT binding, in and of itself, does not shift serum thermograms. 
While significant shifts in rat serum thermogram parameters were 
observed following chronic treatment with GRFT, those shifts do not appear to be 
attributed to the direct binding activity of GRFT.  Serum spiked with varying 
concentrations of GRFT and allowed to react for approximately 1 hour did not 
display alterations in serum thermograms.  With spiking concentrations greatly 
exceeding those concentrations observed in serum following system 
administration, it was believed that any characteristic binding changes would be 
observed by saturation with GRFT.  Given the lack of thermogram alteration in 
spiked samples, it would appear that alterations in serum thermograms following 
chronic GRFT treatment can be attributed to an immune response or alteration of 






GRFT is capable of specific binding to proteins which do not possess 
oligomannose glycans 
Given GRFT’s long serum persistence observed following single and 
chronic dosing, DSC and AP studies were conducted to detail the potential 
interaction of GRFT with a number of ligands.  Fluorometry results confirmed 
specific binding activity of GRFT to a number of saccharide ligands including 
glucose, mannose, maltose, mannan, and N-acetylglucosamine.  These 
interactions have been observed in other previous studies.   Further, affinity 
purification of human serum proteins with both FLAG-GRFT and FLAG-GRFTlec- 
fusion proteins revealed a number of potentially relevant biological interactions.  
Among these, interactions with complement and apoplipoproteins were the most 
numerous in FLAG-GRFT purified groups.  These data would confirm specific 
binding interactions beyond N-linked oligomannose binding activity.  However, 











In summary, GRFT has displayed persistent anti-viral activity in serum, 
even in the presence of an immune response, following systemic administration.  
Further, physiologically relevant concentrations can remain in serum days 
following subcutaneous administration.  While long-term dosing may induce 
biochemical changes and may have an immunosuppressive effect that will 
require additional study, it would appear that subchronic dosing of GRFT is 
tolerable.    Additionally, while lacking oral bioavailability in rats, oral 
administrations of GRFT may have utility.  A small fraction of orally dosed GRFT 
can pass into the rectal mucosa via fecal material. This transit of active GRFT 












RECOMMENDATIONS FOR FURTHER STUDY 
While GRFT is still a strong candidate for anti-viral prophylaxis and 
therapy, a number of questions have been raised by these studies.  It is 
recommended that further research be conducted to address these questions. 
What is the primary mode of GRFT degradation? 
The studies in this work have consistently shown that GRFT can persist in 
serum for a long period of time.  However, the vast majority of GRFT dosed 
disappears within 24 hours of dosing.  Mass Balance experiments revealed only 
a small fraction of GRFT was excreted through the kidneys after an initial burst of 
excretion.  Thus, it would appear that GRFT is degraded in some other manner.  
Therefore, radiolabeling experiments may be necessary to follow GRFT’s journey 
through systemic circulation.  The radiolabeling could also be useful in tracking 
the extent of GRFT’s distribution as well as persistence in specific organ groups. 
What impact does GRFT have upon the kidneys? 
Sub-chronic dosing of GRFT did display changes in kidney size when an 
immune response was induced.  However, at the day 55 of the study, 
pathological differences were not observable between kidneys.  A long term 
administration of GRFT in the presence of an immune response may be required 
in order to clearly delineate alterations in kidney structure and function.  It is also 
recommended that blood nitrogen urea, creatinine clearance, and total 
glomerular filtration rate be tracked over the course of treatment.  These may 
provide valuable insights into GRFT’s effect on the kidneys. 
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Does GRFT cause immunosuppression or immunotoxicity? 
 Sub-chronic dosing of GRFT in rats was observed to lower some 
inflammatory cytokine levels in comparison to adjuvant pre-immunized animals 
and PBS-treated controls.  Further, affinity purification of human serum revealed 
complement factors were recovered by FLAG-GRFT and FLAG-GRFTlec-.  This 
suggests that GRFT administration may have some immunosuppressive or 
immunotoxic effect that could impair an immune response to invading pathogens.  
Accordingly, it is suggested that GRFT complement binding be confirmed by 
binding ELISA as well as the nature of GRFT’s mode of action to rule out a 
functional depletion of complement.  Therefore, additional in vivo and in vitro 
tests will need to be carried to out determine whether GRFT impairs humoral 
response, cellular responses of T-cells, natural killer cells, macrophages, or 
granulocytes.  Further, testing of host resistance to infection (bacterial, viral, and 
tumor) will be necessary, with a concomitant observation for illness. 
Can concentrations of active GRFT found in fecal matter be increased? 
Oral dosing studies discovered that active GRFT is excreted in fecal 
matter.  Given that HIV infection often entails exposure of fluids to rectal mucosa, 
GRFT’s presence in fecal material passing through the rectum may enable its 
usage as a rectal microbicide.  It is possible that GRFT presence in fecal material 
will be able to seed rectal mucosa with potentially protective concentrations of 
GRFT.  However, mass balance studies detailed only limited passage of active 
GRFT.  Accordingly studies into methods of increasing active concentrations of 
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GRFT may further highlight GRFT’s potential as an orally dosed rectal 
microbicide.  These could include dosage of GRFT concurrent with antacids, 
protease inhibitors, or in nanoparticle suspension or controlled release 
encapsulation.  Further, experiments with radiolabeled GRFT may be useful to 
determine whether degraded GRFT is systemically absorbed. 
Does GRFT treatment affect the gut microbiome? 
While GRFT may be a promising orally dosed rectal microbicide, its 
impact on the gut microbiome will need to be assessed.  The gut microbiome can 
be crucial in health, as well as immune system function and regulation [Citations 
needed].  Agents which alter the endogenous balance can result in loss of 
beneficial bacteria or a blooming of harmful bacteria.  Given that some bacteria, 
such as E. coli use mannose for adhesion [243, 244], it is possible that GRFT 
presence could compete with endogenous flora for mannose or other adhesion 
molecules.  Accordingly, a tracking of the speed and nature of gut microbiome 
changes over long term oral administration of GRFT will be necessary to 
eliminate the potential that oral GRFT treatment could result in negative health 
consequences. 
Determine the nature of GRFT’s interaction with apolipoproteins and complement 
GRFT’s binding to human serum proteins has been documented in this 
study.  Particularly relevant were binding interactions with complement and 
apolipoproteins.  In particular, the binding with complement could have 
physiological relevance.  Complement deficiencies have been associated with 
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autoimmune disease.  Thus, a functional depletion of complement through 
binding interactions with GRFT in a chronic administration model could 
potentially exacerbate those disease associations.  Accordingly, determining the 
nature of those interactions will be necessary.  Experiments entailing surface 
plasmon resonance assays, isothermal titration calorimetry, and biotin tag affinity 
switching using a photosensitive cross-linker may yield important information 
regarding specific binding interactions with GRFT. 
How does chronic administration of GRFT affect serum thermograms? 
Spiking of rat serum with GRFT did not alter thermogram parameters.  
However, chronic administration of GRFT resulted in significant changes in 
comparison to PBS treated controls.  However, the exact causative nature of 
these changes are unknown.  DSC can yield information as to characteristic 
changes that occur, but is limited to describe the exact nature of the protein 
interactions causing the change.  Accordingly, quantitative studies will be 
necessary into the abundance of lower molecular weight proteins present in 
altered samples.  It is recommended that these chronic dosing studies be 
repeated solely for the purpose of comparing the alterations in lower molecular 
weight proteins.  Cytokine panels may yield rough concentration changes in 
GRFT treated groups.  Further, MS analysis may be useful in identifying changes 
in serum components – however, Ig and Serum Albumin depletion may be 
required before sample processing to remove signal masking by the more 
abundant proteins.   
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Whether GRFT can be utilized in long term therapy (>6 month)  
Studies to date have yielded positive results in examining GRFT’s 
potential as a systemic therapeutic for viruses possess N-linked, oligomannose 
glycans.  However, given the changes observed in a 55-day treatment regimen, 
longer-term studies will be necessary to determine the true extent of changes 
induced.  Parameters such as kidney weight, blood urea nitrogen, spleen weight, 
and anti-GRFT antibody activity should be monitored to determine whether 
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HCV Hepatitis C Virus 
HGB Hemoglobin 
HIV Human Immunodeficiency Virus 
HPLC High Performance Liquid Chromatography 
HSV Herpes Simplex Virus 
ID50 Inhibitory Dilution 
IFN Interfereon 
Ig  Immunoglobulin   




IP Interfereon Inducible Protein 
IP-10 Interfereon Inducible Protein 10 
JEV Japanese Encephalitis Virus 
kDa Kilodaltons 
KSHV Karposi's Sarcoma Associated herpesvirus 
Ly Lymphocytes 
MBL Mannose Binding Lectin 
MCHC Mean Corpuscular Hematocrit Concentration 
MCP Monocyte Chemotactic protein 
MCV Mean Corpuscular Volume  
MIP Macrophage Inflammatory Protein 
Mo Monocytes 
MPV Mean Platelet Volume 
MSM Men who have sex with men 
PBMC Peripheral Blood Mononuclear cell 
PBS Phosphate Buffered Saline 
PBS-T Phosphate Buffered Saline - Tween 20 




PrEP Pre-Exposure Prophylaxis 
RBC Red Blood Cells    
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RDW Red Blood Cell Width 
RNA Ribonucleic acid 
SARS-Cov 
Ser 
Sudden Acute Respiratory Syndome CoronaVirus 
Serine 
SVN Scytovirin 
TasP Treatment as Prevention 
Tbil Total Bilirubin 
TBS Tris Buffered Saline 
Tfm 
Thr 
First Moment Temperature 
Threonine 
Tmax Maximum Temperature 
TMB 3,3'5,5'-tetramethylbenzidine 
TMV Tobacco Mosaic Virus 
TP Total Protein 
Vd Volume of Distribution 
VEGF Vascular Endothelial Growth Factor 
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